[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1110
1. Maounis N, Chorti M, Legaki S, Ellina E, Emmanouilidou A, Demonakou M, Tsiafaki X: Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature. Diagn Pathol; 2010;5:82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature.
  • Breast metastasis from extra-mammary malignancy is rare.
  • The primary malignancies most commonly metastasizing to the breast are leukemia-lymphoma, and malignant melanoma.
  • We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with extensive micropapillary component, diagnosed concomitantly with the primary tumor.
  • Additionally, on physical examination a poorly defined mass was noted in the upper outer quadrant of the left breast.
  • The patient underwent bronchoscopy, excisional breast biopsy and medical thoracoscopy.
  • By cytology, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal pleura was diagnosed.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Mammography. Predictive Value of Tests. Thoracoscopy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2000 Apr;19(4):257-62 [10759349.001]
  • [Cites] J Surg Oncol. 2010 Feb 1;101(2):137-40 [20082359.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1825-6 [12820464.001]
  • [Cites] Med Oncol. 2003;20(2):181-4 [12835522.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 [19875957.001]
  • [Cites] Mod Pathol. 2010 May;23(5):654-61 [20173733.001]
  • [Cites] Diagn Pathol. 2010;5:37 [20565809.001]
  • [Cites] Am Surg. 2004 Apr;70(4):287-90 [15098776.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Acta Oncol. 1992;31(4):479 [1632985.001]
  • [Cites] South Med J. 1997 Oct;90(10):1063-4 [9347825.001]
  • [Cites] Australas Radiol. 1998 Feb;42(1):16-9 [9509597.001]
  • [Cites] Acta Chir Belg. 2005 Feb;105(1):59-61 [15790204.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):366-7 [16848849.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Australas Radiol. 2007 Apr;51(2):133-8 [17419856.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):731-7 [17582626.001]
  • [Cites] South Med J. 2007 Aug;100(8):850-1 [17715476.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1333-41 [18042689.001]
  • [Cites] Arch Pathol Lab Med. 2008 Feb;132(2):239-43 [18251583.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):426-32 [18300807.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):682-7 [18048381.001]
  • [Cites] Pathology. 2008 Jun;40(4):345-51 [18446623.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1299-301 [18505069.001]
  • [Cites] APMIS. 2009 Oct;117(10):762-7 [19775345.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 Oct;57(10):534-9 [19830516.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • (PMID = 21167048.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC3018363
  •  go-up   go-down


2. Hummel JL, Safroneeva E, Mossman KL: The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther; 2005 Dec;12(6):1101-10
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.
  • Using an immunocompetent murine model of breast adenocarcinoma we demonstrate that the ICP0 mutant KM100 completely eradicates tumors in approximately 80% of treated animals and significantly increases survival.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Genetic Therapy / methods. Herpesvirus 1, Human / metabolism. Immediate-Early Proteins / genetics. Interferons / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140040.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 9008-11-1 / Interferons; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / Vmw110 protein, Human herpesvirus 1
  •  go-up   go-down


3. Stover TC, Sharma A, Robertson GP, Kester M: Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res; 2005 May 1;11(9):3465-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
  • Here, we report that the systemic i.v. delivery of C6-ceramide (C6) in a pegylated liposomal formulation significantly limited the growth of solid tumors in a syngeneic BALB/c mouse tumor model of breast adenocarcinoma.
  • Confirming the therapeutic utility of i.v. liposomal-C6 administration, we also shown diminution of solid tumor growth in a human xenograft model of breast cancer.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Animals. Apoptosis / drug effects. Caveolae / metabolism. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Female. Humans. Injections, Intravenous. Liposomes. Mice. Mice, Inbred BALB C. Mice, Nude. Microscopy, Confocal. Mitochondria / metabolism. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / prevention & control. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867249.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL66371
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ceramides; 0 / Liposomes; 038753E78J / N-caproylsphingosine
  •  go-up   go-down


Advertisement
4. Schachter HM, Mamaladze V, Lewin G, Graham ID, Brouwers M, Sampson M, Morrison A, Zhang L, O'Blenis P, Garritty C: Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review. BMC Cancer; 2006 Dec 18;6:291
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review.
  • BACKGROUND: Breast cancer in women is increasingly frequent, and care is complex, onerous and expensive, all of which lend urgency to improvements in care.
  • METHODS: Ten databases, including Medline, were searched electronically to identify measures assessing the quality of breast cancer care in women (diagnosis, treatment, followup, documentation of care).
  • Eligible studies measured adherence to standards of breast cancer care in women diagnosed with, or in treatment for, any histological type of adenocarcinoma of the breast.
  • RESULTS: Sixty relevant reports identified 58 studies with 143 indicators assessing adherence to quality breast cancer care.
  • ASCO's current development of a set of quality measures relating to breast cancer care may hold the key to conducting definitive studies.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Nov 27;354(9193):1896-900 [10584742.001]
  • [Cites] Health Aff (Millwood). 2004 May-Jun;23(3):89-99 [15160806.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):701-7 [10649266.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] Qual Life Res. 2000;9(6):603-15 [11236851.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1676-87 [11250997.001]
  • [Cites] MedGenMed. 2001 Mar 5;3(2):2 [11549951.001]
  • [Cites] Health Aff (Millwood). 2001 May-Jun;20(3):82-90 [11585185.001]
  • [Cites] Qual Life Res. 2001;10(7):587-93 [11822792.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):459-65 [12017333.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4381-93 [12409338.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2985-91 [15284249.001]
  • [Cites] Evid Rep Technol Assess (Summ). 2004 Sep;(105):1-8 [15503541.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):191-7 [7999464.001]
  • [Cites] Ann Oncol. 1997 Sep;8(9):825-35 [9358933.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):1000-5 [9749483.001]
  • [Cites] J Formos Med Assoc. 1999 Apr;98(4):254-60 [10389369.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):84-8 [10482198.001]
  • [Cites] Med Care. 2003 Jan;41(1 Suppl):I39-47 [12544815.001]
  • [Cites] Med Care. 2003 Jan;41(1 Suppl):I48-60 [12544816.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2635-45 [12826639.001]
  • [Cites] Res Nurs Health. 1999 Dec;22(6):449-60 [10630287.001]
  • (PMID = 17176480.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 290-02-0021
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 28
  • [Other-IDs] NLM/ PMC1764760
  •  go-up   go-down


5. Tsao SC, Su YC, Wang SL, Chai CY: Use of caveolin-1, thyroid transcription factor-1, and cytokeratins 7 and 20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin. Kaohsiung J Med Sci; 2007 Jul;23(7):325-31
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of caveolin-1, thyroid transcription factor-1, and cytokeratins 7 and 20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin.
  • The objectives of this study were firstly to compare the immunostaining patterns of antibodies against caveolin-1, thyroid transcription factor-1 (TTF-1), cytokeratin 7 (CK7) and cytokeratin 20 (CK20) in primary and secondary pulmonary adenocarcinomas of breast or colonic origin, and secondly, to investigate their use alone and in combination, in distinguishing between primary and secondary lung adenocarcinomas from breast or colonic origin.
  • Of the 49 lung adenocarcinoma specimens that were enrolled in this study, 30 were primary pulmonary adenocarcinomas, and 19 (9, breast origin; 10, colonic origin) were metastatic pulmonary carcinomas.
  • Primary pulmonary adenocarcinoma most often had the CK7-positive/CK20-negative immunohistochemical phenotype and was either TTF-1 positive or caveolin-1 negative.
  • Secondary pulmonary adenocarcinoma of breast origin most often had the CK7-positive/CK20-negative immunohistochemical phenotype and was either TTF-1 negative or caveolin-1 positive, while secondary pulmonary adenocarcinoma of colonic origin most often had the CK20-positive/CK7-negative immunohistochemical phenotype and was either TTF-1 negative or caveolin-1 positive.
  • The results suggest that caveolin-1, TTF-1, or CK7/CK20 alone did not distinguish reliably between primary and secondary pulmonary adenocarcinomas originating from breast or colon.
  • The use of a panel of antibodies that includes TTF-1, caveolin-1, and CK7/CK20 may have higher sensitivity in discriminating between primary adenocarcinomas and metastatic lung adenocarcinomas from breast or colonic origin.
  • [MeSH-major] Adenocarcinoma / chemistry. Breast Neoplasms / pathology. Caveolin 1 / analysis. Colonic Neoplasms / pathology. DNA-Binding Proteins / analysis. Keratin-20 / analysis. Keratin-7 / analysis. Lung Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606426.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / DNA-Binding Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / TTF1 protein, human
  •  go-up   go-down


6. Baranzelli MC, Giard S, Cabaret V, Chauvet MP, Robin YM, Vilain MO, Carpentier P, Belkacémi Y, Bonneterre J: [Breast adenocarcinoma: critical analysis of sentinel lymph node histopathological results of 542 procedures]. Bull Cancer; 2005 Nov;92(11):983-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast adenocarcinoma: critical analysis of sentinel lymph node histopathological results of 542 procedures].
  • [Transliterated title] Adénocarcinomes mammaires: analyse critique des résultats histopathologiques des ganglions sentinelles, à propos de 542 cas.
  • Between February 2001 and March 2003, 542 sentinel lymph node procedures were performed for localised breast carcinoma (T0-T1, N0, M0) without any previous treatment.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16316832.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Tham TM, Iyengar KR, Taib NA, Yip CH: Fine needle aspiration biopsy, core needle biopsy or excision biopsy to diagnose breast cancer - which is the ideal method? Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):155-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy, core needle biopsy or excision biopsy to diagnose breast cancer - which is the ideal method?
  • BACKGROUND: The ideal method for diagnosis of breast cancer is debatable.
  • METHODS: The methods of diagnosis of 436 new cases of breast adenocarcinoma presenting from Jan 2005 till Dec 2006 at the University Malaya Medical Centre (UMMC) were examined in this study.
  • RESULTS: A total of 388 cases presented to the breast unit in UMMC primarily and 48 cases were diagnosed in non-breast units in other hospitals and referred for management.
  • Fine needle aspiration cytology (FNAC) was the commonest mode of initial diagnosis in 278 cases followed by core needle biopsy and surgical excision.
  • CONCLUSION: The biopsy method used to confirm the diagnosis is influenced by where the patient first presents, and by the size of the tumour.
  • [MeSH-major] Adenofibroma / diagnosis. Biopsy / methods. Breast Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469645.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


8. Ho YY, Lee WK: Metastasis to the breast from an adenocarcinoma of the colon. J Clin Ultrasound; 2009 May;37(4):239-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the colon.
  • Metastases to the breast from extramammary malignancies are rare.
  • We report a case of metastasis to the breast from a colonic adenocarcinoma in a 50-year-old man who was 6 years status after a right hemicolectomy for T3N1M1 adenocarcinoma of the ascending colon.
  • Sonographic evaluation of the right breast lump showed a hypoechoic mass with slightly irregular margins, but there was no internal vascularity.
  • Chest CT also documented a poorly enhancing suspicious mass in the right breast.
  • The diagnosis of adenocarcinoma metastasis to the breast was achieved with sonographically guided core biopsy.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Breast Neoplasms / ultrasonography. Colonic Neoplasms / pathology. Ultrasonography, Mammary / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18461602.001).
  • [ISSN] 1097-0096
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Menezes AV, Lima MP, Mendonca JE, Haiter-Neto F, Kurita LM: Breast adenocarcinoma mimicking temporomandibular disorders: a case report. J Contemp Dent Pract; 2008;9(5):100-6
MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast adenocarcinoma mimicking temporomandibular disorders: a case report.
  • AIM: The aim of this report is to present a case of a metastatic lesion in the mandible originating from a breast adenocarcinoma that was initially diagnosed as temporomandibular disorder (TMD).
  • Further clinical, radiological, and histological examinations coupled with a history of adenocarcinoma of the breast lead to a final diagnosis of a metastatic lesion in the right TMJ region.
  • Thus the dentist should be able to perform an adequate diagnosis and play an important role in the diagnostic phase of care that can lead to a useful palliation and an enhanced quality of the patient's life.
  • The challenge is to know and evaluate the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Mandibular Neoplasms / secondary. Temporomandibular Joint Disorders / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Mandibular Condyle / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633475.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Brück P, Vilches Cisneros N, Ramos López E, Barboza Quintana O, Ancer Rodríguez J, Flores Gutiérrez JP: [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients]. Ginecol Obstet Mex; 2006 Oct;74(10):516-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
  • [Transliterated title] Expresión del Her2-Neu en el adenocarcinoma ductal de la glándula mamaria: correlación con parámetros histopatológicos y expresión de receptores estrogénicos en pacientes mexicanas.
  • BACKGROUND: Breast cancer is a general health problem that annually produces 400,000 deaths worldwide.
  • Its early diagnosis leads to high cure rates; nevertheless, in Mexico City this happens rarely.
  • Her2-Neu is an oncogene that is expressed on breast cancer cells, with aggressive behaviour and metastasis.
  • OBJECTIVE: To know the biology and distribution of Her2-Neu expression in Mexican breast cancer patients in order to evaluate its potential as a prognostic and predictive factor in the treatment of the breast cancer.
  • PATIENTS AND METHOD: In the cases of invasive ductal adenocarcinomas of the breast we compared by immunohistochemistry the Her2-Neu and estrogen receptor expressions with the histopathological characteristics.
  • RESULTS: We found 122 cases of breast adenocarcinoma, from which we evaluated 108 for fulfilling the selection criteria of invasive ductal adenocarcinoma.
  • CONCLUSIONS: Since the percentage of patients with Her2-Neu expression is high (36.1%) and there is a close relation between Her2-Neu expression, the tumour size and the presence of lymph node methastasis, the determination of the oncoprotein expression could allow a more detailed prognosis and the treatment with immunotherapy and anthracyclines in order to influence the course of the breast cancer cases.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Genes, erbB-2. Neoplasm Proteins / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21961357.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


11. Strik MW, Anders S, Barth M, Bärlehner E, Benecke C, Benhidjeb T: [Total videoendoscopic thyroid resection by the axillobilateral breast approach. Operative method and first results]. Chirurg; 2007 Dec;78(12):1139-44
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total videoendoscopic thyroid resection by the axillobilateral breast approach. Operative method and first results].
  • [Transliterated title] Total-videoendoskopische Strumaresektion via "axillobilateral breast approach". Operative Technik und erste Ergebnisse.
  • BACKGROUND: The axillobilateral breast approach (ABBA) is a procedure allowing thyroid resection without scarring at the neck.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Cysts / surgery. Endoscopes. Minimally Invasive Surgical Procedures / instrumentation. Surgical Instruments. Thyroid Diseases / surgery. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery. Thyroidectomy / instrumentation. Video-Assisted Surgery / instrumentation
  • [MeSH-minor] Adult. Axilla / innervation. Axilla / surgery. Biopsy, Needle. Female. Humans. Intraoperative Complications / diagnosis. Intraoperative Complications / prevention & control. Middle Aged. Monitoring, Intraoperative / instrumentation. Recurrent Laryngeal Nerve Injuries. Reoperation. Thyroid Gland / pathology. Ultrasonic Therapy / instrumentation. Vocal Cord Paralysis / diagnosis. Vocal Cord Paralysis / prevention & control

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurg. 2001 Sep;72(9):1054-7 [11594276.001]
  • [Cites] J Endocrinol Invest. 1999 Dec;22(11):849-51 [10710272.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1075-8 [15490052.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Dec;12(6):426-9 [12496549.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201 [12819505.001]
  • [Cites] Surg Endosc. 1997 Aug;11(8):877 [9266657.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5 [12598753.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • (PMID = 17805497.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Granata A, Figura M, Gulisano S, Romeo G, Sicurezza E, Failla A, Scuderi R: [Central diabetes insipidus as a first manifestation of lung adenocarcinoma]. Clin Ter; 2007 Nov-Dec;158(6):519-22
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central diabetes insipidus as a first manifestation of lung adenocarcinoma].
  • [Transliterated title] Diabete insipido centrale come prima manifestazione di adenocarcinoma polmonare.
  • Metastases to the pituitary gland are absolutely rare, and they are generally secondary to pulmonary carcinoma in men and breast carcinoma in women.
  • Bronchoscopy and biopsy demonstrated a pulmonary adenocarcinoma.
  • Thus, we made a diagnosis of lung cancer with local and pituitary metastases.
  • In conclusion, in patients presenting with sudden onset of diabetes insipidus pituitary metastases should be taken in account in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diabetes Insipidus / etiology. Lung Neoplasms / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / secondary
  • [MeSH-minor] Biopsy. Bronchoscopy. Diagnosis, Differential. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Polyuria / etiology. Thirst. Tomography, X-Ray Computed


13. Aghi M, Kiehl TR, Brisman JL: Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature. J Neurooncol; 2005 Nov;75(2):149-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
  • We report a case of breast carcinoma metastatic to an epidural cervical meningioma, summarize the literature on metastases to central nervous system meningiomas, and suggest a possible mechanism.
  • Because of concern that the fracture and epidural lesion might represent metastases, we performed a metastatic work-up, which revealed a right breast mass.
  • Intraoperative frozen section revealed mixed meningioma and breast adenocarcinoma.
  • Mechanisms of this unusual process likely include meningiomas' vascularity, meningiomas' slow growth providing nutrient availability, and perhaps, as suggested by our analysis, E-cadherin expression by both meningiomas and breast cancer.
  • Metastasis to meningioma must be considered in an epidural spinal lesion in all patients with a known malignancy, with surgical aggressiveness tailored to the intraoperative pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Cervical Vertebrae / pathology. Meningioma / diagnosis. Meningioma / secondary. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for breast adenocarcinoma .
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1978;40(3-4):307-13 [676808.001]
  • [Cites] Zentralbl Allg Pathol. 1983;127(5-6):367-74 [6880445.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Sep 15;27(18):E403-5 [12634576.001]
  • [Cites] J Neurosurg. 1963 Oct;20:892-4 [14186085.001]
  • [Cites] J Neurosurg. 1961 Sep;18:688-9 [13733931.001]
  • [Cites] South Med J. 1977 Apr;70(4):503-5 [191937.001]
  • [Cites] N Y State J Med. 1970 Oct 15;70(20):2592-8 [5272944.001]
  • [Cites] Arch Intern Med. 1989 Apr;149(4):959-62 [2650648.001]
  • [Cites] Neurosurg Rev. 1994;17(3):233-6 [7838405.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Neurol. 2002 Oct;249(10):1357-69 [12382150.001]
  • [Cites] Arch Pathol Lab Med. 1980 Jul;104(7):392-3 [6893129.001]
  • [Cites] J Neurosurg. 1951 Mar;8(2):185-97 [14824981.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1975;366(1):87-91 [804761.001]
  • [Cites] South Med J. 1976 Apr;69(4):514-7 [1265521.001]
  • [Cites] Ann Oncol. 1992 May;3(5):409-10 [1616896.001]
  • [Cites] JAMA. 1972 Jan 17;219(3):384 [5066633.001]
  • [Cites] Am J Pathol. 1930 Jan;6(1):47-52.1 [19969886.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] Acta Neurol Belg. 1996 Dec;96(4):329-31 [9008785.001]
  • [Cites] Mod Pathol. 1994 Sep;7(7):752-61 [7824509.001]
  • [Cites] Cancer. 1976 May;37(5):2232-7 [177186.001]
  • [Cites] Cancer. 1978 Oct;42(4):1992-4 [213189.001]
  • [Cites] Tumori. 1996 Sep-Oct;82(5):491-3 [9063531.001]
  • [Cites] Am J Clin Oncol. 2002 Aug;25(4):414-7 [12151976.001]
  • [Cites] JAMA. 1970 Jun 22;212(12):2124 [5467793.001]
  • [Cites] J Neurosurg Sci. 1992 Jul-Sep;36(3):169-72 [1484305.001]
  • [Cites] Br J Neurosurg. 2002 Feb;16(1):66-8 [11926470.001]
  • [Cites] Acta Neurochir (Wien). 1981;58(1-2):67-74 [7282462.001]
  • [Cites] Surg Neurol. 1996 Nov;46(5):458-63; discussion 463-4 [8874546.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1975 Jul;38(7):695-7 [1159441.001]
  • [Cites] Neurology. 1997 Aug;49(2):452-6 [9270576.001]
  • [Cites] Magn Reson Med. 2004 Jun;51(6):1122-8 [15170831.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Jun-Jul;19(6):1120-2 [9672023.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1081-4 [3300947.001]
  • [Cites] J Korean Med Sci. 2000 Oct;15(5):593-7 [11069000.001]
  • [Cites] Arch Pathol Lab Med. 1980 Jul;104(7):350-4 [6893121.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Arch Anat Cytol Pathol. 1978;26(3-4):175-6 [749691.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2001;49(2):171-4 [11348022.001]
  • [Cites] J Neurosurg. 1957 May;14(3):337-43 [13429401.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4028-33 [10632335.001]
  • [Cites] Tumori. 2001 Nov-Dec;87(6):423-7 [11989598.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;405(1):155-60 [6438898.001]
  • [Cites] J Neurosurg. 1963 Sep;20:801-4 [14185000.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer. 1981 Dec 15;48(12 ):2668-73 [7306923.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):510-3 [11696622.001]
  • [Cites] AJR Am J Roentgenol. 2001 Dec;177(6):1479-81 [11717111.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):31-6 [9516949.001]
  • [Cites] Am J Pathol. 1952 Sep-Oct;28(5):757-91 [12976523.001]
  • [Cites] Arch Pathol Lab Med. 1980 Jul;104(7):394-5 [6893130.001]
  • [Cites] Pathol Res Pract. 1993 May;189(4):399-404 [8351240.001]
  • (PMID = 16132512.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Nitriles; 0 / PIP protein, human; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  • [Number-of-references] 57
  •  go-up   go-down


14. Carvalho S, Branco R, Serralheiro P, Saraiva T, Carvalho L: [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University]. Rev Port Pneumol; 2006 May-Jun;12(3):255-68
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University].
  • [Transliterated title] Adenocarcinoma do pulmão: Aplicação da classificação WHO 1999/2004 à casuística do Serviço de Anatomia Patológica do Hospital da Universidade de Coimbra.
  • A study of 701 primary adenocarcinomas of the lung was made at the Department of Pathology of the Hospital da Universidade de Coimbra for a period of fifteen years, between 1990 and 2004.
  • In the same period 382 metastases were diagnosed, mainly from colon (119) and breast (66).
  • In the last four years, since 2001, patients were in the seventies at the time of diagnosis and a considerable number of cases were diagnosed after 80 years of age.
  • A number of 109 cases had the final diagnosis of adenocarcinoma of the lung based on morphology and immunohistochemistry criteria.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. International Classification of Diseases. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967175.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


15. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ho AS, Huang X, Cao H, Koong AC, Le QT: Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):4624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients.
  • : 4624 Background: MicroRNAs (miRs) are small non-coding transcripts involved in many cellular mechanisms, including tumorigenesis. miR-210, in particular, has been shown to be induced by hypoxia, over-expressed in several different cancers, and correlated with adverse outcomes in breast cancer.
  • Its expression is significantly higher in the blood of pancreatic cancer patients compared to controls and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964211.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain.
  • : e21526 Background: Primary sarcomas of the breast (PBS) are a heterogeneous group of tumors from stromal breast, infrequent (0.1% of BC).
  • Diagnosis and treatment is unclear.
  • Contralateral low grade AS in one woman, and lung adenocarcinoma in the man, had been diagnosed 2 years later.
  • CONCLUSIONS: PBS are rare and difficult diagnosis tumors.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • Our incidence was high, but the independent pathology analysis confirmed all histopathological diagnosis.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kayali F, Janjua MA, Laber DA, Miller DM, Day JM, Kloecker GH: Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiologic studies also have shown beneficial effects of digitalis in breast cancer incidence.
  • All patients had unresectable stage III/IV at diagnosis.
  • Histologies were 50% adenocarcinoma, 30% squamous and 20% unspecified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962216.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The median interval from the diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 months (range, 0 - 73.1 months).
  • Median OS duration from diagnosis of LMC was 6.7 weeks (95% CI; 4.3-9.1 weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Delbaldo C, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah J, Fabbro M, Quinaux E, Association Européenne de Recherche en Oncologie (AERO): Analysis of the impact of growth factor on the haematological safety of dose-dense regimen in the randomized phase II adjuvant trial BO3. J Clin Oncol; 2009 May 20;27(15_suppl):605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred patients with node-positive invasive breast adenocarcinoma were randomized between (arm A) docetaxel 75 mg/m<sup>2</sup>, epiribucin 75 mg/m<sup>2</sup> and cyclophosphamide 500 mg/m<sup>2</sup> (TEC) every 3 weeks for 6 cycles (35 patients) or (arm B) epiribucin 100 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every 2 weeks for 4 cycles, followed by T 100 mg/m<sup>2</sup> (EC→T) every 2 weeks for 4 cycles (31 patients) or (arm C) T→ EC (34 patients).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961470.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pandya NK, Auerbach JD, Baldwin K, Lackman RD, Chin KR: Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report. Spine (Phila Pa 1976); 2006 Nov 15;31(24):E920-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report.
  • SUMMARY OF BACKGROUND DATA: To our knowledge, there have been no previous reports of spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine.
  • The patient's mass was found to be breast adenocarcinoma metastatic to osteochondromas of the spine.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / diagnosis. Exostoses, Multiple Hereditary / complications. Neoplasms, Unknown Primary / diagnosis. Spinal Cord Compression / etiology. Spinal Neoplasms / secondary. Thoracic Vertebrae / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chondrosarcoma / diagnosis. Combined Modality Therapy. Decompression, Surgical. Diagnosis, Differential. Female. Humans. Laminectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Paclitaxel / administration & dosage. Spinal Fusion. Tomography, X-Ray Computed. Trastuzumab


23. Xu WG, Yang K, Fang N, Dai D, Yu JP, Wei F, Song XY, Zhu YJ, Wang J, Men XY, Zhang Y: [Growing characteristic of breast adenocarcinoma suicide gene cell line T47D-tk and construction of subcutaneous xenografts]. Zhonghua Yi Xue Za Zhi; 2009 Feb 17;89(6):423-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growing characteristic of breast adenocarcinoma suicide gene cell line T47D-tk and construction of subcutaneous xenografts].
  • OBJECTIVE: To further identify the breast adenocarcinoma cell line T47D-tk stably expressing the suicide gene HSV1-tk, observe its growing characteristics, and establish an animal model of implanted breast adenocarcinoma.
  • METHODS: Retroviral vector of HSV1-tk gene and breast carcinoma cell line T47D-tk stably expressing the HSV1-tk gene were established.
  • Breast carcinoma cells of the lines T47D and T47D-tk were cultured, and observed by inverted microscope.
  • An animal model of implanted breast cancer has been successfully established.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, Transgenic, Suicide / genetics. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567126.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


24. Shidham VB, Komorowski RA, Machhi JK: Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol; 2006;1:34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary.
  • BACKGROUND: The differential diagnosis of metastatic mammary adenocarcinoma and adenocarcinomas from other primary sites can be challenging, particularly in tumors that are poorly differentiated and negative for Estrogen/Progesterone receptors (ER/PR).
  • This study was undertaken to evaluate the diagnostic significance of AR expression in adenocarcinoma of breast and other morphologically similar adenocarcinomas.
  • DESIGN: Formalin-fixed paraffin-embedded tissue sections of 113 primary adenocarcinoma of various sites [breast (34, all females), lung (23, M- 6, F-17), colon (9, M-2, F-7), stomach (6, M-4, F-2), liver and bile duct (11, M-5, F-6), pancreas (7, M-2, F-5), ovary (10), endometrium (7), and cervix (6)] were immunostained with monoclonal antibody for AR.
  • Except for well differentiated lobular carcinoma of breast (5) and bronchoalveolar carcinoma of lung (10), majority of the tumors were moderately to poorly differentiated.
  • RESULTS: 56% (19/34) mammary carcinoma and 20% (2/10) adenocarcinoma of ovary were positive for AR.
  • If metastatic tumor with unknown primary in a female is AR positive, breast and ovary are the most likely primary sites.
  • Cytoplasmic immunoreactivity alone without nuclear immunoreactivity for AR was non-specific for this differential diagnosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30 [7528632.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1428-32 [9865828.001]
  • [Cites] J Am Acad Dermatol. 1995 May;32(5 Pt 1):711-6 [7722013.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):119-22 [10697267.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):579-86 [10757407.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):745-50 [12090423.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):651-8 [12146025.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):801-6 [12817426.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):581-4 [1399140.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):725-31 [14608899.001]
  • [Cites] Int Rev Cytol. 1975;41:87-172 [166046.001]
  • [Cites] J Histochem Cytochem. 1991 Jul;39(7):927-36 [1865110.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):7162-7 [2582456.001]
  • [Cites] J Steroid Biochem. 1987 Mar;26(3):393-7 [3495702.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):539-42 [4007019.001]
  • [Cites] J Pathol. 1993 May;170(1):31-5 [8100853.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):783-8 [8189040.001]
  • [Cites] Hum Pathol. 1993 Jan;24(1):90-5 [8418017.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] Mod Pathol. 1995 Dec;8(9):897-901 [8751328.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1175-80 [8883401.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3803-6 [9042261.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):839-45 [9267828.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1033-8 [9831198.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1122-6 [9831211.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • (PMID = 17020615.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1601970
  •  go-up   go-down


25. Ozer N, Deveci OS, Okutucu S, Demircin M: Asymptomatic right atrial myxoma originating from the inferior vena cava and right atrium junction in a patient with breast ductal adenocarcinoma. Turk Kardiyol Dern Ars; 2009 Oct;37(7):479-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic right atrial myxoma originating from the inferior vena cava and right atrium junction in a patient with breast ductal adenocarcinoma.
  • We present asymptomatic right atrial myxoma in a patient with breast ductal adenocarcinoma.
  • She had a 10-month history of modified radical mastectomy for ductal adenocarcinoma of the breast, followed by adjuvant chemotherapy.
  • The tumor was completely excised and histopathologic diagnosis was myxoma.
  • Localization of right atrial myxoma at the junction of the inferior vena cava and right atrium is a rare condition, and its coexistence with breast carcinoma has only been reported once.
  • [MeSH-major] Adenocarcinoma / complications. Breast Neoplasms / complications. Carcinoma, Ductal / complications. Heart Atria / pathology. Heart Neoplasms / complications. Myxoma / complications. Vena Cava, Inferior / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098042.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


26. Chvapil M: Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens. Anticancer Drugs; 2005 Feb;16(2):201-10
Hazardous Substances Data Bank. (D)-PENICILLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aminopropionitrile / therapeutic use. Antineoplastic Agents / therapeutic use. Mammary Neoplasms, Animal / drug therapy. Penicillamine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BETA-AMINOPROPIONITRILE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655419.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Esters; 0 / Fibrillar Collagens; 151-18-8 / Aminopropionitrile; GNN1DV99GX / Penicillamine
  • [Number-of-references] 39
  •  go-up   go-down


27. Misiewicz-Krzemińska I, Skupińska K, Graczyk A, Kasprzycka-Guttman T: Influence of protoporphyrin IX amino acid substituents on affinity to human breast adenocarcinoma MCF-7 cells. Biotech Histochem; 2009 Feb;84(1):17-23
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of protoporphyrin IX amino acid substituents on affinity to human breast adenocarcinoma MCF-7 cells.
  • The ability of protoporphyrin IX (PP IX) to enter neoplastic cells is used for diagnosis and photodynamic therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Protoporphyrins / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115117.001).
  • [ISSN] 1473-7760
  • [Journal-full-title] Biotechnic & histochemistry : official publication of the Biological Stain Commission
  • [ISO-abbreviation] Biotech Histochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids, Diamino; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 94ZLA3W45F / Arginine
  •  go-up   go-down


28. Bannur HB, Mastiholimath RD, Malur PR: Primary mucinous eccrine adenocarcinoma of the scalp: a case report. Acta Cytol; 2009 Nov-Dec;53(6):698-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous eccrine adenocarcinoma of the scalp: a case report.
  • Metastatic deposits from undiagnosed visceral and breast adenocarcinoma are virtually indistinguishable microscopically from sweat gland carcinoma and must be considered before a diagnosis of sweat gland carcinoma is made.
  • A diagnosis of mucinous eccrine adenocarcinoma was given.
  • CONCLUSION: Primary mucinous adenocarcinoma of the skin is a rare tumor and mimics metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Eccrine Glands / pathology. Scalp / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014562.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Saglam A, Can B: Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman. J Clin Pathol; 2005 Jan;58(1):87-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman.
  • A 36 year old pregnant woman was admitted to hospital complaining of an enlarging mass in her left breast.
  • Histopathological examination of the mastectomy specimen revealed a high grade infiltrating ductal adenocarcinoma intermixed with a lactating adenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplasms, Multiple Primary / pathology. Pregnancy Complications, Neoplastic / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] Cancer. 1954 Mar;7(2):318-24 [13141224.001]
  • [Cites] Pathol Int. 2002 Mar;52(3):244-8 [11972869.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 3:iii31-6 [12821536.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):44-50 [12756565.001]
  • [Cites] Cancer. 1976 Jun;37(6):2891-905 [949710.001]
  • [Cites] Lancet. 1989 Feb 4;1(8632):252 [2563418.001]
  • [Cites] Acta Cytol. 1990 Jan-Feb;34(1):21-6 [2153326.001]
  • [Cites] Histopathology. 1993 May;22(5):481-5 [8344658.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1220-8 [8826943.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] Pharmacol Ther. 1998 Aug;79(2):169-78 [9749881.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Apr;13(2):311-32 [10363133.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):389-404 [10516853.001]
  • [Cites] Breast J. 2001 Sep-Oct;7(5):354-7 [11906446.001]
  • (PMID = 15623491.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770558
  •  go-up   go-down


30. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr, Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest; 2005 Jan;35(1):60-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four peptide hormones decrease the number of human breast adenocarcinoma cells.
  • METHODS AND MATERIALS: These six hormones, each at their 1-microm concentrations, were evaluated for their ability to decrease the number and/or proliferation of breast adenocarcinoma cells in culture for 24, 48, 72, and 96 h.
  • RESULTS: Within 24 h, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, atrial natriuretic peptide and 8-bromo-cyclic GMP, a cell-permeable analogue of their intracellular mediator cyclic GMP (each at 1 microm), decreased the number of breast adenocarcinoma cells 60%, 31%, 27%, 40%, and 31%, respectively.
  • There was no proliferation in the 3 days following this decrease in breast adenocarcinoma cell number.
  • Brain natriuretic peptide and CNP did not decrease the number of breast adenocarcinoma cells or inhibit their DNA synthesis.
  • Natriuretic peptide receptors-A and -C were present in the breast adenocarcinoma cells.
  • CONCLUSIONS: Four peptide hormones significantly decrease the number of human breast adenocarcinoma cells within 24 h and inhibit the proliferation of these cells for at least 96 h.
  • [MeSH-major] Adenocarcinoma / drug therapy. Breast Neoplasms / drug therapy. Hormones / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638821.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / atrial natriuretic factor precursor (79-98); 0 / atrial natriuretic factor prohormone (1-30), human; 0 / atrial natriuretic factor prohormone (31-67); 114471-18-0 / Natriuretic Peptide, Brain; 127869-51-6 / Natriuretic Peptide, C-Type; 85637-73-6 / Atrial Natriuretic Factor; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Atrial Natriuretic Factor; EC 4.6.1.2 / atrial natriuretic factor receptor A; EC 4.6.1.2 / atrial natriuretic factor receptor C
  •  go-up   go-down


31. Dedes I, Ziogas V: Simultaneous diagnosis and treatment of bilateral breast carcinoma and endometrial adenocarcinoma. Implications for screening. Eur J Gynaecol Oncol; 2008;29(5):515-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous diagnosis and treatment of bilateral breast carcinoma and endometrial adenocarcinoma. Implications for screening.
  • The association of breast and endometrial carcinoma has been demonstrated by many studies.
  • Most of the cases are related to the previous use of tamoxifen for the treatment of breast carcinoma.
  • This is an unusual case regarding simultaneous diagnosis and treatment of bilateral breast carcinoma and endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Ductal / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051825.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Solari HP, Ventura MP, Cheema DP, Odashiro AN, Burnier MN Jr: Orbital metastasis from breast carcinoma presenting as neurotrophic keratitis. Can J Ophthalmol; 2006 Feb;41(1):93-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis from breast carcinoma presenting as neurotrophic keratitis.
  • CASE REPORT: This is a case report of an 81-year-old woman with previous breast cancer.
  • Light microscopy findings suggested the diagnosis of orbital metastatic breast carcinoma that was confirmed by immunohistochemistry.
  • The histopathologic diagnosis was metastatic adenocarcinoma of the breast to the left orbit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462881.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW: Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol; 2010 Apr;38(4):264-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of malignant mesothelioma in serosal effusions continues to be a major challenge because some of its cytomorphological features closely resemble adenocarcinomas.
  • In this study, we evaluated the value of immunostaining pattern for podoplanin to differentiate mesothelioma from adenocarcinomas of various origins.Cell blocks from previously collected paraffin-embedded cell blocks of 86 effusions (18 mesothelioma, 35 reactive mesothelium, 9 breast adenocarcinoma, 14 ovarian adenocarcinoma, and 10 lung adenocarcinoma) were retrieved from the file of the Department of Pathology at University of Michigan and Lund University in Sweden and were used for the study.
  • The intensity of positive results was evaluated as strong, moderate, or weak.Podoplanin is expressed in 94% of malignant mesothelioma cases (17/18), 97% (30/31) of cases of reactive mesothelial, 0% of lung adenocarcinoma cases (0/9), 0% of breast adenocarcinoma (0/9), and 7% of ovarian adenocarcinoma (1/14).
  • The one positive case of ovarian adenocarcinoma showed a weak membranous podoplanin immunostaining.On the basis of our results and published data, we believe that membranous podoplanin immunoreactivity, in conjunction with calretinin, would be more specific than CK5/6 and WT-1 in differentiating epithelioid malignant mesothelioma from adenocarcinoma of the lung, breast, and ovary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Membrane Glycoproteins / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 20146302.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


34. Boutis AL, Andreadis C, Patakiouta F, Mouratidou D: Gastric signet-ring adenocarcinoma presenting with breast metastasis. World J Gastroenterol; 2006 May 14;12(18):2958-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric signet-ring adenocarcinoma presenting with breast metastasis.
  • Breast metastases from gastric cancer are extremely rare.
  • A case report of a 37-year-old female with breast inflammatory invasion and ascites is described.
  • Breast biopsy revealed carcinomatous invasion of the lymphatics from adenocarcinoma cells with signet-ring features.
  • Histopathologic examination of the lesion showed infiltration from a high-grade adenocarcinoma, identical with that of the breast.
  • Ascitic fluid cytology was positive for adenocarcinoma cells.
  • The patient died six months after initial diagnosis.
  • [MeSH-major] Breast Neoplasms / secondary. Carcinoma, Signet Ring Cell / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Adult. Ascites. Carcinoembryonic Antigen / analysis. Female. Humans. Immunohistochemistry. Keratin-20. Keratin-7. Keratins / analysis. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2004 Mar;29(3):167-70 [15162986.001]
  • [Cites] Cancer. 1976 Feb;37(2):828-40 [175913.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2520-4 [7438025.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1830-7 [6269726.001]
  • [Cites] J Surg Oncol. 1989 Dec;42(4):264-6 [2556613.001]
  • [Cites] J Surg Oncol. 1991 Oct;48(2):117-21 [1656147.001]
  • [Cites] Mod Pathol. 1993 Sep;6(5):516-20 [8248106.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):191-5 [7898116.001]
  • [Cites] Clin Nucl Med. 1996 Feb;21(2):115-7 [8697679.001]
  • [Cites] Pediatr Hematol Oncol. 1996 May-Jun;13(3):277-85 [8735345.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1293-300 [8960043.001]
  • [Cites] J Korean Med Sci. 1997 Jun;12(3):256-61 [9250925.001]
  • [Cites] Yonsei Med J. 2000 Oct;41(5):669-72 [11079630.001]
  • [Cites] Br J Radiol. 2000 Dec;73(876):1326-8 [11205680.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • [Cites] Surgery. 2002 Nov;132(5):889-93 [12464875.001]
  • [Cites] Ann Oncol. 2003 May;14(5):803-4 [12702537.001]
  • (PMID = 16718828.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC4087820
  •  go-up   go-down


35. Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, Sato Y, Aoyama H, Hayashi T, Kushima R: Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol; 2008 May;39(5):666-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
  • Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast have close histologic similarities.
  • We examined 23 serous papillary adenocarcinomas (16 ovarian, 5 endometrial, and 2 peritoneal) and 37 invasive micropapillary carcinomas of the breast (12 pure and 25 mixed types) on immunohistochemical expression of Wilm's tumor antigen-1 (WT1), CA125, and gross cystic disease fluid protein-15 (GCDFP-15), which have been reported to be useful in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
  • The CA125-positive rate of invasive micropapillary carcinoma was higher than the rate reported for other types of breast carcinomas.
  • We consider CA125 to be not always useful in the differential diagnosis of serous papillary adenocarcinoma and invasive micropapillary carcinoma.
  • Although the positive rate of WT1 was significantly higher in serous papillary adenocarcinoma than in invasive micropapillary carcinoma, WT1 expression in endometrial serous papillary adenocarcinoma was infrequent (20%).
  • WT1 and GCDFP-15 could be useful markers for the differential diagnosis of ovarian and peritoneal serous papillary adenocarcinoma versus breast invasive micropapillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. CA-125 Antigen / analysis. Carrier Proteins / analysis. Endometrial Neoplasms / diagnosis. Genital Neoplasms, Female / diagnosis. Glycoproteins / analysis. Ovarian Neoplasms / diagnosis. WT1 Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339419.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / WT1 Proteins
  •  go-up   go-down


36. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • We describe metastatic adenocarcinoma of unknown primary presenting as a pericardial effusion and coincident supraclavicular adenopathy.
  • Two years after initial diagnosis, the patient expired because of disease progression.
  • Although immunohistochemical staining initially suggested metastatic breast carcinoma, her clinical course confirmed a lung primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


37. Taguchi Y, Takashima S, Inoue Y, Nagata T, Shimizu M, Tanaka K: [Case of antiamphiphysin antibody-positive stiff-person syndrome with breast cancer diagnosed by FDG-PET]. Rinsho Shinkeigaku; 2008 Jun;48(6):410-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of antiamphiphysin antibody-positive stiff-person syndrome with breast cancer diagnosed by FDG-PET].
  • We report a case of antiamphiphysin antiboddy-positive stiff-person syndrome associated with breast cancer, which was detected only by FDG-PET.
  • However, mammogram, thoracic CT, breast MRI and ultrasonic echography showed no abnormal findings.
  • Then, the left axillary lymph nodes were resected and immunohistochemically diagnosed as breast adenocarcinoma.
  • Treatment of stiff-person syndrome was initiated with corticosteroids followed by chemotherapy against breast cancer, which led to a remarkable improvement of her neurological symptoms.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / radionuclide imaging. Autoantibodies / blood. Breast Neoplasms / complications. Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Nerve Tissue Proteins / immunology. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / etiology. Positron-Emission Tomography. Radiopharmaceuticals. Stiff-Person Syndrome / diagnosis. Stiff-Person Syndrome / etiology

  • Genetic Alliance. consumer health - Stiff person syndrome.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616152.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / Nerve Tissue Proteins; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 147954-52-7 / amphiphysin
  • [Number-of-references] 12
  •  go-up   go-down


38. Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, Moore HC, Andresen S, Crowe JP: Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol; 2007 Dec;16(4):207-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
  • We report our experience with primary FISH testing in 742 consecutive cases of breast cancer, in the calendar year 2006.
  • Eighty percent (595/742) of the breast cancer cases were not amplified for HER2 (HER2/CEP17=0.8-1.9), whereas 19% (142/742) of cases were HER2 amplified (HER2/CEP17>or=2.0).
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043283.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


39. Xu WG, Dai D, Fang N, Song XY, Wang J, Zhu YJ, Men XY: [Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice]. Zhonghua Yi Xue Za Zhi; 2009 Dec 29;89(48):3420-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice].
  • OBJECTIVE: To study the in vitro accumulation of (18)F-FHBG, its in vivo distribution and (18)F-FHBG PET-CT imaging for reporter gene (HSV1-tk) in nude mice with a xenograft of breast adenocarcinoma.
  • METHODS: The in vitro uptake of (18)F-FHBG in tumor cells of T47D and T47D-tk and the distribution of (18)F-FHBG in normal Kunming mice and nude mice with breast adenocarcinoma xenograft were detected by well-type gamma counter.
  • Reporter gene PET-CT imaging with (18)F-FHBG was performed in nude mice with a xenograft of breast adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Breast Neoplasms / radionuclide imaging. Genes, Reporter. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223118.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 9-(4-fluoro-3-hydroxymethylbutyl)guanine; 0 / Fluorine Radioisotopes; 5Z93L87A1R / Guanine
  •  go-up   go-down


40. Wang C, Zhou XG: [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Apr;35(4):228-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma].
  • OBJECTIVE: To study the expression of CDX2 in normal and tumor tissues, and to evaluate the value of CDX2 immunostaining in the diagnosis of gastrointestinal adenocarcinoma.
  • RESULTS: CDX2 was strongly expressed in surface epithelium of 13 samples of normal intestine and in ductal epithelium of 8 samples of normal pancreas, as well as in 47 samples (92.2%) of colonic adenocarcinoma and 58 samples (66.9%) of gastric adenocarcinoma.
  • The positivity rates were as follows: ovarian mucinous adenocarcinoma 15.6% (10/64), pancreatic cancer 33.3% (3/9), thyroid cancer 27.3% (3/11) and extrahepatic biliary cancer 25% (4/16).
  • On the other hand, primary tumors of breast, prostate, kidney, adrenal and liver were negative for CDX2.
  • CONCLUSIONS: CDX2 is expressed mainly in normal epithelium of intestinal tract and small pancreatic ducts, as well as in primary adenocarcinoma of gastrointestinal tract.
  • CDX2 may thus play an important role in distinguishing primary non-intestinal adenocarcinoma from metastatic adenocarcinoma of gastric or colorectal primary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastrointestinal Neoplasms / diagnosis. Homeodomain Proteins / metabolism
  • [MeSH-minor] Colonic Neoplasms / diagnosis. Colonic Neoplasms / metabolism. Female. Gastrointestinal Tract / chemistry. Gastrointestinal Tract / pathology. Humans. Immunohistochemistry. Male. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776981.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


41. Kumaraguruparan R, Chandra Mohan KV, Nagini S: Xenobiotic-metabolising enzymes in patients with adenocarcinoma of the breast: correlation with clinical stage and menopausal status. Breast; 2006 Feb;15(1):58-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xenobiotic-metabolising enzymes in patients with adenocarcinoma of the breast: correlation with clinical stage and menopausal status.
  • Adenocarcinoma of the breast is the most common cancer in women worldwide and its incidence is increasing in most countries.
  • The present study was designed to evaluate the relationship between different clinical stages and menopausal status using the activity of phase I and II carcinogen-metabolising enzymes in breast cancer patients.
  • Fifty breast cancer patients clinically categorized as stage I, II and III, and as pre- and postmenopausal were chosen for the study.
  • Enhanced levels of cytochrome P450 and b(5) and phase II enzyme activity were observed in breast tumour tissues compared with the corresponding uninvolved adjacent tissues irrespective of clinical stage and menopausal status of the patients.
  • Our results suggest that the balance between phase I carcinogen activation and phase II detoxification systems may play an important role in the development of breast tumours.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Breast Neoplasms / enzymology. Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002293.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Xenobiotics
  •  go-up   go-down


42. Fadiora SO, Mabayoje VO, Aderoumu AO, Adeoti ML, Olatoke SA, Oguntola AS: Generalised Burkitt's lymphoma involving both breasts--a case report. West Afr J Med; 2005 Jul-Sep;24(3):280-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma involving the breast is an unusual clinical entity, which is rarely distinguished preoperatively from other more common forms of breast cancer.
  • The Management differs from the more typical adenocarcinoma of the breast in that the emphasis is on systemic therapy.
  • She was diagnosed histologically as primary breast Burkitt's lymphoma.
  • She had a recurrence of the lesion in the right breast a month later that was excised.
  • CONCLUSION: Compared with breast carcinoma, primary breast lymphoma is a rare disease but should be considered in the differential diagnosis of breast masses.
  • [MeSH-major] Breast Neoplasms / pathology. Burkitt Lymphoma / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16276714.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


43. Cissell KA, Rahimi Y, Shrestha S, Hunt EA, Deo SK: Bioluminescence-based detection of microRNA, miR21 in breast cancer cells. Anal Chem; 2008 Apr 1;80(7):2319-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioluminescence-based detection of microRNA, miR21 in breast cancer cells.
  • The assay was employed for the detection of miR21 in human breast adenocarcinoma MCF-7 cells and nontumorigenic epithelial MCF-10A cells.
  • The comparison of miR21 expression level in two cell lines demonstrated higher expression of miR21 in breast cancer cell line MCF-7 compared to the nontumorigenic MCF-10A cells.
  • The need for early molecular markers and their detection methods in cancer diagnosis is tremendous.
  • The characteristics of the assay developed in this work show its suitability for early cancer diagnosis based on miRNA as a biomarker.
  • [MeSH-major] Breast Neoplasms / genetics. Luminescent Measurements / methods. MicroRNAs / analysis. MicroRNAs / genetics. RNA, Neoplasm / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302417.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB008231-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


44. Herbst J, Jenders R, McKenna R, Marchevsky A: Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section. Am J Clin Pathol; 2009 Jan;131(1):122-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section.
  • The distinction between primary lung adenocarcinoma and metastatic breast carcinoma in patients with a history of breast cancer is difficult by frozen section (FS) analysis.
  • Our experience with 129 FSs from 121 patients with a pulmonary nodule and a history of breast cancer was reviewed.
  • The pretest odds ratio of primary pulmonary carcinoma/metastatic breast carcinoma was 2.6.
  • The incidence of 12 histopathologic features was assessed in a "training set" composed of 20 FSs, 10 with primary lung adenocarcinoma and 10 with metastatic breast cancer.
  • A differential diagnosis model composed of significant pathologic features that favor the diagnosis of primary lung adenocarcinoma (acini, lepidic growth, nuclear pseudoinclusions, and scar) or metastatic breast carcinoma (comedonecrosis, solid nests, trabecular architecture, and cribriform growth) was identified.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / pathology. Frozen Sections / methods. Lung Neoplasms / diagnosis
  • [MeSH-minor] Breast / pathology. Breast Neoplasms, Male / pathology. Diagnosis, Differential. Evidence-Based Medicine. Female. Humans. Male. Pathology, Clinical / education. Sensitivity and Specificity. Thorax / pathology


45. Al-Kalaldeh JZ, Abu-Dahab R, Afifi FU: Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells. Nutr Res; 2010 Apr;30(4):271-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells.
  • In the present study, selected spices used in Jordan were chemically analyzed and investigated for their antiproliferative activity to the adenocarcinoma of breast cell line (MCF7).
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiosperms / chemistry. Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Cell Proliferation / drug effects. Oils, Volatile / therapeutic use. Terpenes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534330.001).
  • [ISSN] 1879-0739
  • [Journal-full-title] Nutrition research (New York, N.Y.)
  • [ISO-abbreviation] Nutr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Oils, Volatile; 0 / Plant Extracts; 0 / Rhodamines; 0 / Terpenes; 2609-88-3 / lissamine rhodamine B
  •  go-up   go-down


46. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR: The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol; 2005 Apr;36(4):348-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
  • Clinical and in vitro evidence supports the concept that human epidermal growth factor receptor-2 ( HER2 ) gene amplification prediction of response to anthracycline-based chemotherapy in breast cancer is not a direct effect of HER2 overexpression, but the result of coamplification of topoisomerase II-alpha ( TOP2A ).
  • One hundred thirty-eight cases of breast cancer HER2 gene amplified by 2-color FISH ( HER2 /CEP17) were reevaluated with a 3-color probe set ( HER2 /CEP17/ TOP2A ) to investigate the frequency of coamplification and deletion of TOP2A .
  • The current study demonstrates the complex interrelationship between the HER2 and TOP2A genes in breast cancer.
  • The clinical implications of TOP2A amplification and deletion in breast cancer need to be further defined.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Genes, erbB-2


47. Adibelli ZH, Yildirim M, Ozan E, Oztekin O, Kucukzeybek B: Fibroadenoma of the breast in a man associated with adenocarcinoma of the rectum and polyposis coli. JBR-BTR; 2010 Jan-Feb;93(1):12-4
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibroadenoma of the breast in a man associated with adenocarcinoma of the rectum and polyposis coli.
  • Fibroadenoma of the breast is an uncommon cause of breast lumps in men.
  • We present herein the first case of a fibroadenoma of the breast in a 68-year-old man with adenocarcinoma of the rectum and polyposis coli.
  • Fibroadenomas in men without hormone treatment and with normal hormone levels are extremely rare and the developmental mechanism of the breast fibroadenoma in this man is under question.
  • [MeSH-major] Adenocarcinoma / complications. Adenomatous Polyposis Coli / complications. Breast Neoplasms, Male / complications. Fibroadenoma / complications. Rectal Neoplasms / complications
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Mammography. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397428.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


48. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • The original breast tumor was typical of cribriform DCIS.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152281.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Dib LL, Soares AL, Sandoval RL, Nannmark U: Breast metastasis around dental implants: a case report. Clin Implant Dent Relat Res; 2007 Jun;9(2):112-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast metastasis around dental implants: a case report.
  • BACKGROUND: Metastases to the oral cavity and to the jaws are rare; hence, the clinical manifestations of the oral metastasis lesion could frequently be simulating general pathologic entities, making the diagnosis a challenging process to the dental team.
  • RESULTS: Clinical examination, x-ray, and histopathology revealed that the patients suffered from a metastatic lesion, primary tumor being an adenocarcinoma of the breast diagnosed at the same time.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Dental Implants. Gingival Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535335.001).
  • [ISSN] 1523-0899
  • [Journal-full-title] Clinical implant dentistry and related research
  • [ISO-abbreviation] Clin Implant Dent Relat Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Dental Implants
  •  go-up   go-down


50. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol; 2005 Sep;29(9):1221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
  • Breast carcinomas with amplification of HER2 on chromosome 17 are associated with HER2 protein overexpression, adversely affecting prognosis and predicting response to Herceptin therapy.
  • This impact was investigated in breast carcinomas identified by fluorescence in situ hybridization (FISH) to have a gain of chromosome 17 (CEP17+; n = 56), using a dual probe assay, which detects HER2 gene copy number and enumerates chromosome 17 (HER2/CEP17; Vysis).
  • These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17 / genetics. Genes, erbB-2 / physiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096413.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


51. Njiaju UO, Truica CI: Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report. Clin Breast Cancer; 2010 Feb;10(1):E3-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
  • Prostate adenocarcinoma can manifest as a fairly indolent tumor or as a very aggressive cancer with significant invasive and metastatic potential.
  • We present a case of a man who presented with breast skin changes that mimicked inflammatory breast carcinoma with specialized testing ultimately giving a diagnosis of metastatic prostatic adenocarcinoma.
  • A 78-year-old man presented with left breast redness and swelling.
  • A breast ultrasound showed no focal mass, and a breast core biopsy had no evidence of tumor.
  • Subsequent immunohistochemical staining on the tumor specimen was positive for prostate-specific antigen (PSA) and alpha-methyl-CoA-racemase, confirming a diagnosis of metastatic prostatic adenocarcinoma.
  • Prostatic adenocarcinoma presenting initially as a breast malignancy is a rarely recognizable clinical event.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms, Male / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133250.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Vinothini G, Nagini S: Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast. Clin Chim Acta; 2010 Mar;411(5-6):368-74
MedlinePlus Health Information. consumer health - Menopause.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast.
  • BACKGROUND: Adenocarcinoma of the breast is the most common cancer worldwide and accounts for the highest morbidity and mortality.
  • The increasing global incidence of breast cancer emphasizes the need to understand the molecular mechanisms of breast tumorigenesis.
  • The present study was designed to correlate changes in xenobiotic-metabolizing enzymes (XME), oxidative stress and NFkappaB signaling with histological grading and menopausal status in breast cancer patients.
  • METHOD: Sixty breast cancer patients histologically categorized as grades I, II and III, and as pre- and postmenopausal were chosen for the study.
  • RESULTS: The breast tumors analyzed in the present study were characterized by increased activities of xenobiotic-metabolizing enzymes and enhanced oxidative damage to lipids, proteins, and DNA associated with variations in the expression of NFkappaB family members.
  • The magnitude of the changes was however more pronounced in premenopausal patients and in grade III breast tumors.
  • CONCLUSION: The present study delineates the correlation between XME-mediated oxidative stress and NFkappaB signaling that leads to the development of breast cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Cytochrome P-450 Enzyme System / metabolism. Menopause. NF-kappa B / metabolism. Oxidative Stress. Xenobiotics / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19995559.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Xenobiotics; 9035-51-2 / Cytochrome P-450 Enzyme System
  •  go-up   go-down


53. McKeon A, Ahlskog JE, Britton JW, Lennon VA, Pittock SJ: Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol; 2009 Feb;66(2):268-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient 1, a woman aged 63 years, experienced hemiparesis with hemianopia 3 years after a diagnosis of adenocarcinoma of the breast.
  • Patient 2, a woman aged 79 years, presented with monoparesis and epilepsia partialis continua, 1 year after a diagnosis of adenocarcinoma of the breast.
  • Subacute onset of aphasia, delirium, worsening seizures, and rising ANNA-1 titers led to a diagnosis of recurrent limited carcinoma.
  • [MeSH-minor] Aged. Biomarkers / analysis. Breast Neoplasms / complications. Carcinoma / complications. Cognition Disorders / drug therapy. Cognition Disorders / immunology. Disease Progression. Female. Humans. Immunotherapy. Lung Neoplasms / complications. Magnetic Resonance Imaging. Male. Middle Aged. Paresis / drug therapy. Paresis / immunology. Seizures / drug therapy. Seizures / immunology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Neurol. 2009 Jul;66(7):916 [19597101.001]
  • [ErratumIn] Arch Neurol. 2011 Mar;68(3):371. Britton, Jeffrey A [corrected to Britton, Jeffrey W]
  • (PMID = 19204167.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


54. Su YC, Hsu YC, Chai CY: Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci; 2006 Jan;22(1):14-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
  • Thyroid transcription factor-1 (TTF-1), and cytokeratin 7 (CK7) and cytokeratin 20 (CK20) have recently been reported to be useful to distinguish between primary and metastatic lung adenocarcinoma.
  • The aim of this study was to determine the usefulness of the staining patterns of pulmonary adenocarcinoma with antibodies to TTF-1, CK7, and CK20 in differentiating primary from metastatic pulmonary adenocarcinoma.
  • Of the 66 lung adenocarcinoma specimens that were enrolled in our study, there were 40 primary lung adenocarcinomas, 12 metastatic adenocarcinomas from breast, 13 metastatic adenocarcinomas from colon, and 1 metastatic adenocarcinoma from stomach.
  • CK7 expression was significantly more frequent in adenocarcinomas of pulmonary and breast origin than gastrointestinal (GI) origin (p < 0.001).
  • In contrast, CK20 expression was significantly more prevalent in adenocarcinoma that originated in the GI tract than that of pulmonary or breast origin (p < 0.001).
  • A combination of TTF-1+CK7+CK20- was highly significantly associated with primary adenocarcinoma of lung (vs GI tract, p < 0.001; vs breast, p < 0.001).
  • A combination of TTF-1-CKCK20+ was highly significantly associated with adenocarcinoma of GI origin (vs lung, p < 0.001; vs breast, p < 0.001).
  • Our study has confirmed that expression of CK7, CK20, and TTF-1 is a useful immunohistochemical marker for diagnosis of lung tumors and for differential diagnosis of primary pulmonary adenocarcinomas from extrapulmonary adenocarcinomas metastatic to the lung.
  • Application of this panel of antibodies might be expected to increase the accuracy of diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Keratins / analysis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570563.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


55. McLean SR, Shousha S, Francis N, Lim A, Eccles S, Nathan M, Brock CS, Palmieri C: Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. J Cutan Pathol; 2007 Dec;34(12):934-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
  • We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy.
  • A punch biopsy of the breast lesion resulted in a diagnosis of metastatic invasive ductal carcinoma (IDC) of the breast.
  • Both the morphological and the immunohistochemical characteristics of the tumor were consistent with a revised diagnosis of DEA rather than IDC.
  • This case emphasizes the challenge in discriminating histopathologically between two rare tumors of the male breast, namely DEA and IDC.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms, Male / pathology. Carcinoma, Ductal, Breast / pathology. Eccrine Glands / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18001417.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 094ZI81Y45 / Tamoxifen; 114084-78-5 / ibandronic acid; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Fereidooni F, Kovacs K, Azizi MR, Nikoo M: Skin metastasis from an occult esophageal adenocarcinoma. Can J Gastroenterol; 2005 Nov;19(11):673-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin metastasis from an occult esophageal adenocarcinoma.
  • They usually originate from primary tumours in the breast, lung or colon.
  • Skin metastases from esophageal adenocarcinoma are extremely rare.
  • A biopsy revealed metastatic adenocarcinoma, and subsequent investigations detected the primary tumour in the esophagus, despite no symptoms.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292362.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


57. French FP, Murray PM, Perdikis G: Extensive cutaneous metastatic breast carcinoma of the hand and upper extremity: a case report. J Hand Surg Am; 2007 Feb;32(2):252-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive cutaneous metastatic breast carcinoma of the hand and upper extremity: a case report.
  • Cutaneous metastatic breast carcinoma involving the hand is extremely rare.
  • We report a case of a 39-year-old woman with a history of recurrent invasive ductal adenocarcinoma of the breast who had a right modified radical mastectomy, chemotherapy, and radiation therapy before presenting to our institution with extensive cutaneous metastasis to the upper limb including the hand.
  • The presentation, pathogenesis, incidence, prognosis, management, and differential diagnosis of cutaneous metastatic breast carcinoma to the hand and upper limb are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Hand / pathology. Skin Neoplasms / secondary. Upper Extremity / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275603.001).
  • [ISSN] 0363-5023
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Jensen KC, Kong CS: Cytologic diagnosis of columnar-cell lesions of the breast. Diagn Cytopathol; 2007 Feb;35(2):73-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of columnar-cell lesions of the breast.
  • This study describes the cytologic features of breast columnar-cell lesions (CCLs) and determines whether these lesions can be diagnosed by fine-needle aspiration.
  • The prospective diagnosis of CCL cannot reliably be made by fine-needle aspiration.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Aged. Biopsy, Fine-Needle. Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / pathology. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230565.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Simsir A, Chhieng D, Wei XJ, Yee H, Waisman J, Cangiarella J: Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy. Diagn Cytopathol; 2005 Jul;33(1):3-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy.
  • The cytologic diagnosis of primary conventional renal-cell adenocarcinoma (cRCC) is usually straightforward; however, metastatic cRCC must be distinguished from a variety of neoplasms with clear-cell features.
  • CD10, a cell membrane-associated neutral endopeptidase, and renal-cell carcinoma marker (RCCma), an antibody against human proximal tubular brush border antigen, have recently been shown to be useful in the diagnosis of cRCC.
  • We compared CD10 and RCCma in cell block material from fine-needle aspiration biopsies (FNABs) to assess their utility in the diagnosis of metastatic cRCC, in cytologic specimens.
  • The immunoreactivity results were compared with those of a variety of neoplasms originating from other sites such as the liver, lungs, breast, and the gastrointestinal tract.
  • We conclude that CD10 has limited value in confirming the diagnosis of cRCC because of its low specificity.
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kidney / chemistry. Kidney / pathology. Male. Middle Aged. Neoplasm Metastasis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc
  • (PMID = 15945081.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


60. Li S, Lee AK: Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int J Clin Exp Pathol; 2009;3(1):117-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction?
  • A series of anecdotal case reports and a recent epidemiological case-control study have suggested a possible association between silicone implant and the development of primary breast ALK1-negative anaplastic large cell lymphoma (ALCL), a rare type of peripheral T-cell lymphoma.
  • In this report, we describe an additional case of primary breast ALK1-negative ALCL in the fibrous capsule and cystic fluid of silicone breast implant in a 58 year old woman who underwent breast reconstructive surgery after lumpectomy for her infiltrating breast adenocarcinoma.
  • Morphologically and immunohistochemically, the lymphoma cells may be confused with recurrent infiltrating breast adenocarcinoma or other non-hematolymphoid malignancies.
  • We will also review the case reports and case series published in the English literature and discuss our current understanding of silicone implant in primary breast ALK1-negative ALCL.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Breast Implants / adverse effects. Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Diagnosis, Differential. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Reconstructive Surgical Procedures

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):407-13 [18480397.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Am J Hematol. 2009 Mar;84(3):133-9 [19199367.001]
  • [Cites] Plast Reconstr Surg. 2009 Mar;123(3):790-3 [19319041.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):831-3 [19330656.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):918-24 [19373599.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):301-6 [19318917.001]
  • [Cites] Clin Breast Cancer. 2009 Aug;9(3):145-54 [19661037.001]
  • [Cites] Ann Oncol. 2009 Dec;20(12):1993-9 [19570964.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Epidemiology. 2001 May;12(3):321-6 [11337605.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Haematologica. 2004 Apr;89(4):ELT01 [15075114.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):939-42 [7751462.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1341-9 [9308703.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):557-60 [16622125.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Int J Hematol. 2008 Jun;87(5):491-7 [18414980.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008 Jul;61(7):822-5 [17509956.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • (PMID = 19918336.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  • [Other-IDs] NLM/ PMC2776268
  • [Keywords] NOTNLM ; ALCL / ALK1 / Breast implant / anaplastic large cell lymphoma / silicone
  •  go-up   go-down


61. Ishida M, Hotta M, Kushima R, Tsuruoka S, Ohji M, Okabe H: Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland. Rinsho Byori; 2009 Aug;57(8):746-51
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • Ductal adenocarcinoma of the lacrimal gland is extremely rare; to our knowledge, only seven de novo cases and one case of ductal adenocarcinoma ex pleomorphic adenoma have been reported in the literature.
  • Here, we report a case of ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland.
  • A 70-year-old Japanese female received the resection of the recurrent lacrimal gland tumor (second surgery), under the clinical diagnosis of recurrent pleomorphic adenoma, fifteen years after the initial surgical resection.
  • The resected tumor was composed of recurrent pleomorphic adenoma and adenocarcinoma.
  • Adenocarcinoma component showed infiltrative papillo-tubular or microcystic growth of carcinoma cells, which had pleomorphic large nuclei with prominent nucleoli and rich eosinophilic cytoplasm.
  • Accordingly, the diagnosis of ductal adenocarcinoma ex pleomorphic adenoma was made.
  • These data suggests that lacrimal ductal adenocarcinoma appears to have a poor prognosis, similar to salivary duct carcinoma, which is one of the most aggressive salivary carcinoma.
  • And further study is needed to clarify the clinicopathological features of the lacrimal ductal adenocarcinoma.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Eye Neoplasms / diagnosis. Eye Neoplasms / pathology. Lacrimal Apparatus. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764409.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


62. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM: Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol; 2005 Mar;29(3):359-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
  • We concluded that CK17 is a useful marker in separating pancreatobiliary adenocarcinomas from extra-pancreatobiliary nonmucinous adenocarcinomas, including adenocarcinomas from the colon, breast, gynecologic organs, stomach, lung, prostate, thyroid, kidney, and adrenal gland, and malignant mesothelioma.
  • MUC2+/CDX2+ can be used as positive markers for the intestinal-type adenocarcinoma of duodenal papillary origin with a positive predictive value of 82%.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Female. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Keratins / metabolism. Male. Mucins / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725805.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


63. Kumar M, Yigit M, Dai G, Moore A, Medarova Z: Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res; 2010 Oct 1;70(19):7553-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided breast tumor therapy using a small interfering RNA nanodrug.
  • In this study, we describe the synthesis and testing of a tumor-targeted nanodrug (MN-EPPT-siBIRC5) that is designed to specifically shuttle siRNA to human breast tumors.
  • The nanodrug binds the tumor-specific antigen uMUC-1, which is found in >90% of human breast adenocarcinomas.
  • Nanodrug uptake by human breast adenocarcinoma cells resulted in a significant downregulation of BIRC5.
  • Following i.v. delivery into subcutaneous mouse models of breast cancer, the nanodrug showed a preferential tumor uptake, which could be visualized by MRI and near-IR optical imaging.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 AACR.
  • [Cites] EMBO Mol Med. 2009 Jun;1(3):142-51 [20049714.001]
  • [Cites] Methods Mol Biol. 2009;555:1-13 [19495684.001]
  • [Cites] J Control Release. 2010 Mar 19;142(3):416-21 [19919845.001]
  • [Cites] Nanomedicine. 2010 Apr;6(2):344-54 [19699318.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):828-34 [20068551.001]
  • [Cites] Methods Mol Biol. 2010;629:53-67 [20387142.001]
  • [Cites] J Control Release. 2010 May 10;143(3):311-7 [20080139.001]
  • [Cites] Bioconjug Chem. 2000 Nov-Dec;11(6):941-6 [11087345.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):243-7 [12242156.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1821-7 [14996745.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Annu Rev Med. 2005;56:401-23 [15660519.001]
  • [Cites] Nat Biotechnol. 2005 Apr;23(4):457-62 [15778705.001]
  • [Cites] J Immunol Methods. 2005 May;300(1-2):63-73 [15894328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12177-82 [16091473.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2796-802 [16385568.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):689-96 [16863503.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):476-84 [16829204.001]
  • [Cites] Hum Gene Ther. 2006 Oct;17(10):1019-26 [17007568.001]
  • [Cites] Nat Med. 2007 Mar;13(3):372-7 [17322898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4095-100 [17360483.001]
  • [Cites] Nat Protoc. 2006;1(1):429-35 [17406265.001]
  • [Cites] Nature. 2007 Jul 5;448(7149):39-43 [17572664.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1182-9 [19141648.001]
  • [Cites] Cancer Gene Ther. 2009 Mar;16(3):217-26 [18927599.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3464-71 [19336572.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(23):4174-9 [19408274.001]
  • [Cites] Biomaterials. 2010 Apr;31(11):3079-86 [20092889.001]
  • (PMID = 20702603.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R00 CA129070-04; United States / NCI NIH HHS / CA / R00 CA129070; United States / NCI NIH HHS / CA / CA129070-04; United States / NCI NIH HHS / CA / R00CA129070; United States / NCRR NIH HHS / RR / S10 RR025504
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / CY5.5 cyanine dye; 0 / Carbocyanines; 0 / Ferric Compounds; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Peptides; 0 / RNA, Small Interfering; 1K09F3G675 / ferric oxide
  • [Other-IDs] NLM/ NIHMS227761; NLM/ PMC2948644
  •  go-up   go-down


64. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


65. Shir A, Ogris M, Wagner E, Levitzki A: EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med; 2006 Jan;3(1):e6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.
  • With the available treatments, survival does not exceed 12-14 mo from the time of diagnosis.
  • Similarly, non-viral delivery of poly IC completely eliminated pre-established breast cancer and adenocarcinoma xenografts derived from EGFR over-expressing cancer cell lines, suggesting that the strategy is applicable to other EGFR-over-expressing tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Glioblastoma / metabolism. Mammary Neoplasms, Experimental / metabolism. Poly I-C / metabolism. RNA, Double-Stranded / metabolism. Receptor, Epidermal Growth Factor / metabolism. Transfection

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2001 Sep 15;29(18):3882-91 [11557821.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47550-5 [11600500.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):969-75 [16084774.001]
  • [Cites] Cell. 2002 Jan 25;108(2):221-32 [11832212.001]
  • [Cites] Cell Mol Neurobiol. 2001 Dec;21(6):645-56 [12043839.001]
  • [Cites] Nat Biotechnol. 2002 Sep;20(9):895-900 [12205508.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1106-14 [12395320.001]
  • [Cites] Oncology. 2002;63(4):317-32 [12417786.001]
  • [Cites] Hum Gene Ther. 2002 Nov 1;13(16):1971-80 [12427307.001]
  • [Cites] Cancer Immunol Immunother. 2003 May;52(5):342-6 [12700950.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1834-7 [12702570.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2001;66:485-97 [12762051.001]
  • [Cites] Apoptosis. 2003 Jun;8(3):237-49 [12766484.001]
  • [Cites] FASEB J. 2003 Jun;17(9):961-83 [12773480.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23915-21 [12690108.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):173-81 [12932649.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):783-7 [12939468.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):495-506 [14965443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):966-71 [14967457.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):99-107 [14997040.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):817-25 [15027114.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):34-40 [15048678.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3859-61 [8752145.001]
  • [Cites] Apoptosis. 2005 Jan;10(1):153-66 [15711931.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):241-7 [15946581.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):208-9 [16014894.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):77-86 [16078112.001]
  • [Cites] Oncologist. 2005 Aug;10(7):467-70 [16079313.001]
  • [CommentIn] PLoS Med. 2006 Jan;3(1):e31 [16323974.001]
  • [ErratumIn] PLoS Med. 2007 Aug;4(8):e266
  • (PMID = 16318410.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imines; 0 / Polyethylenes; 0 / RNA, Double-Stranded; 0 / poly(ethylene imine); 24939-03-5 / Poly I-C; 30IQX730WE / Polyethylene Glycols; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / eIF-2 Kinase
  • [Other-IDs] NLM/ PMC1298941
  •  go-up   go-down


66. Berthier A, Seguin S, Sasco AJ, Bobin JY, De Laroche G, Datchary J, Saez S, Rodriguez-Lafrasse C, Tolle F, Fraichard A, Boyer-Guittaut M, Jouvenot M, Delage-Mourroux R, Descotes F: High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br J Cancer; 2010 Mar 16;102(6):1024-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer.
  • BACKGROUND: This study evaluates the relation of the early oestrogen-regulated gene gabarapl1 to cellular growth and its prognostic significance in breast adenocarcinoma.
  • Thereafter, by performing macroarray and reverse transcriptase quantitative-polymerase chain reaction (RT-qPCR) experiments, gabarapl1 expression was quantified in several histological breast tumour types and in a retrospective cohort of 265 breast cancers.
  • RESULTS: GABARAPL1 overexpression inhibited MCF-7 growth rate and gabarapl1 expression was downregulated in breast tumours.
  • CONCLUSIONS: Our data show for the first time that the level of gabarapl1 mRNA expression in breast tumours is a good indicator of the risk of recurrence, specifically in pN+ patients.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Microtubule-Associated Proteins / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacogenomics. 2008 Dec;9(12):1879-902 [19072646.001]
  • [Cites] Clin Breast Cancer. 2008 Apr;8(2):168-77 [18621614.001]
  • [Cites] Breast Cancer Res. 2001;3(5):299-303 [11597318.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Aug;3(4):546-62 [12934666.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Nov 26;119(2):216-9 [14625090.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4127-34 [15483022.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Eur J Cancer. 1980 Nov;16(11):1513-5 [6262087.001]
  • [Cites] Mol Cell Endocrinol. 1993 Jan;90(2):R17-21 [8495796.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 10;325(2):639-48 [15530441.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):394-400 [15695379.001]
  • [Cites] J Biol Chem. 2006 Mar 24;281(12):7983-93 [16431922.001]
  • [Cites] Exp Cell Res. 2007 Nov 15;313(19):3971-82 [17927979.001]
  • [Cites] Planta Med. 2007 Nov;73(14):1447-51 [17948189.001]
  • [Cites] Brain Res. 2008 May 19;1210:103-15 [18423580.001]
  • [Cites] Oncologist. 2001;6(4):376-85 [11524557.001]
  • (PMID = 20197771.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / GABARAPL1 protein, human; 0 / Microtubule-Associated Proteins
  • [Other-IDs] NLM/ PMC2844027
  •  go-up   go-down


67. Dhillon R, Depree P, Metcalf C, Wylie E: Screen-detected mucinous breast carcinoma: potential for delayed diagnosis. Clin Radiol; 2006 May;61(5):423-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screen-detected mucinous breast carcinoma: potential for delayed diagnosis.
  • RESULTS: Of the pure mucinous carcinomas, the average age at diagnosis was 65 years (range 48-82 years), which was higher than that of other women with breast cancer (average age 60 years) screened at BreastScreen WA.
  • However, none of these cases had positive axillary lymph nodes at final diagnosis.
  • CONCLUSION: Although mammographically benign appearances of mucinous carcinoma caused a delay in diagnosis in 38% of the present cases, mucinous breast carcinomas have a favourable prognosis, as they are often low-grade tumours and rarely metastasize.
  • Delay in diagnosis for these tumours in a screening programme may not lead to a significant adverse outcome for most women.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / radiography
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Databases, Factual. Female. Humans. Mammography / methods. Middle Aged. Neoplasm Invasiveness. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679116.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Ypma PF, Wijermans PW, Koppen H, Sillevis Smitt PA: Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma. Neth J Med; 2006 Jul-Aug;64(7):243-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration preceding the diagnosis of Hodgkin's lymphoma.
  • PCD can accompany different kinds of neoplasms including small cell lung cancer, adenocarcinoma of the breast and ovary, and Hodgkin's lymphoma.
  • Despite extensive laboratory and radiological evaluations in this patient with rapidly deteriorating cerebellar syndrome, the diagnosis of a paraneoplastic syndrome was only made after several months, when an anti-Tr antibody was detected in his serum.
  • [MeSH-major] Cerebellum / pathology. Hodgkin Disease / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


69. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst; 2005 Jan 19;97(2):142-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
  • BACKGROUND: The incidence of esophageal adenocarcinoma is rising dramatically.
  • METHODS: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results database to extract information on incidence, stage distribution, and disease-specific mortality for esophageal adenocarcinoma as well as information on related cancers.
  • RESULTS: From 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from 4 to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.
  • The only location with increased incidence is the lower third of the esophagus-the site where adenocarcinoma typically arises.
  • Because there has been little change in the proportion of patients found with in situ or localized disease at diagnosis since 1975 (from 25% to 31%) and because esophageal adenocarcinoma mortality has increased more than sevenfold (from 2 to 15 deaths per million), overdiagnosis can be excluded as an explanation for the rise in incidence.
  • CONCLUSION: The rising incidence of esophageal adenocarcinoma represents a real increase in disease burden.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Classification / methods. Confounding Factors (Epidemiology). Cost of Illness. Cross-Sectional Studies. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. SEER Program. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jul 6;97(13):1013-4; author reply 1014 [15998956.001]
  • (PMID = 15657344.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


70. Altinoğlu EI, Russin TJ, Kaiser JM, Barth BM, Eklund PC, Kester M, Adair JH: Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano; 2008 Oct 28;2(10):2075-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer.
  • Early detection is a crucial element for the timely diagnosis and successful treatment of all human cancers but is limited by the sensitivity of current imaging methodologies.
  • PEGylated ICG-CPNPs accumulate in solid, 5 mm diameter xenograft breast adenocarcinoma tumors via enhanced retention and permeability (EPR) within 24 h after systemic tail vein injection in a nude mouse model.
  • [MeSH-major] Breast Neoplasms / pathology. Calcium Phosphates. Drug Carriers / chemistry. Indocyanine Green. Microscopy, Fluorescence / methods. Nanoparticles / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ACS Nano. 2008 Oct 28;2(10):1984-6 [19206441.001]
  • (PMID = 19206454.001).
  • [ISSN] 1936-086X
  • [Journal-full-title] ACS nano
  • [ISO-abbreviation] ACS Nano
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Drug Carriers; 97Z1WI3NDX / calcium phosphate; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


71. Aydin VM, Cekinmez M, Kizilkilic O, Kayaselcuk F, Sen O, Altinors N: Unusual case of skull metastasis secondary to pancreatic adenocarcinoma. Pathol Oncol Res; 2005;11(3):182-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of skull metastasis secondary to pancreatic adenocarcinoma.
  • Skull metastasis must be kept in mind when considering the differential diagnosis of a skull tumor.
  • Despite the fact that hematogenous skull metastases can be caused by nearly all types of tumors (lung, prostate, thyroid carcinoma, malignant melanoma), breast cancer is associated with the highest rate of metastatic skull lesions.
  • We report an extremely rare case of skull metastasis from a pancreatic adenocarcinoma, in a 65-year-old woman, presented with painless frontoparietal scalp swelling which developed within three months.
  • To the best of our knowledge, this is the second case involving the skull secondary to a pancreatic adenocarcinoma, and the first case when skull metastasis was the first evidence of a pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2001 Apr;48(4):745-54; discussion 754-5 [11322434.001]
  • [Cites] Surg Neurol. 1981 Jan;15(1):35-8 [7256522.001]
  • [Cites] Arch Otolaryngol. 1979 Apr;105(4):196-9 [426707.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):209-14 [10680873.001]
  • [Cites] Radiologe. 1988 Mar;28(3):132-3 [2836886.001]
  • [Cites] Bull Acad Natl Med. 1998;182(5):997-1008; discussion 1008-9 [9735503.001]
  • [Cites] Hong Kong Med J. 2002 Apr;8(2):149-51 [11937672.001]
  • [Cites] Surg Neurol. 2003 Sep;60(3):219-25; discussion 225-6 [12922038.001]
  • (PMID = 16195774.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


72. Yamashita R, Matsuzaki M, Matsui T, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Clinical characteristics of prostatic adenocarcinoma with ductal features]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):525-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of prostatic adenocarcinoma with ductal features].
  • PURPOSE: To determine the incidence and prognosis of prostatic ductal adenocarcinoma.
  • We differentiated prostatic cases of ductal adenocarcinoma that were larger than 5 mm in diameter from cases of acinar adenocarcinomas.
  • RESULTS: We found eight cases (12%) of prostatic ductal adenocarcinoma among the 64 cases treated with radical prostatectomies.
  • In addition, one case was identified as pure ductal adenocarcinoma.
  • During the follow-up period, four of the eight cases of ductal adenocarcinoma (50%) and twelve of the 56 cases of acinar adenocarcinoma (21%) showed postoperative PSA failure.
  • CONCLUSIONS: We identified eight cases of ducal adenocarcinoma (12% of the examined cases), which suggests this disease is not as rare as previously reported.
  • Compared to the cases of acinar adenocarcinoma, the cases of ductal adenocarcinoma were at a more advanced pathological stage and resulted in a higher rate of postoperative PSA failure.
  • Therefore, we believe that patients that show even a limited degree of ductal adenocarcinoma should receive aggressive therapy.
  • [MeSH-major] Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404881.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


73. Wagamon K, Ranchoff RE, Rosenberg AS, Jaworsky C: Benign lymphangiomatous papules of the skin. J Am Acad Dermatol; 2005 May;52(5):912-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of benign lymphangiomatous papules of the skin that occurred in a patient 4 years after undergoing radiation therapy to the chest for adenocarcinoma of the breast.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Lymphangioma / pathology. Radiotherapy / adverse effects. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858490.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Bretz-Grenier MF: [Breast cytopathology bestiary]. Ann Pathol; 2006 Oct;26(5):403-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cytopathology bestiary].
  • Breast cytopathology of tubular and lobular carcinomas may be very difficult.
  • Indeed, the classical morphological signs of malignancy are often scarce or absent; the identification of special patterns of cell clusters may therefore be very useful to reach a diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255930.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


75. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Wosnitza M, Rübben A, Pallua N, Megahed M: [Eccrine adenocarcinoma in a patient with familial breast carcinoma]. Hautarzt; 2008 Nov;59(11):879-83
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eccrine adenocarcinoma in a patient with familial breast carcinoma].
  • The histopathologic findings showed eccrine adenocarcinoma, a member of the heterogeneous group of sweat gland tumors which occur primarily in adults with a peak of 50-60 years of age.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Eccrine Glands / pathology. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1989 Sep;42(1):69-72 [2770311.001]
  • [Cites] Cancer. 2003 May 1;97(9):2285-9 [12712485.001]
  • [Cites] Dermatol Surg. 2001 Apr;27(4):401-8 [11298716.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2004 Mar;113(3 Pt 1):242-4 [15053210.001]
  • [Cites] Conn Med. 2000 May;64(5):263-6 [10860232.001]
  • [Cites] J Surg Oncol. 1976;8(1):23-9 [1249938.001]
  • [Cites] World J Surg Oncol. 2003 Aug 1;1(1):13 [12921537.001]
  • [Cites] Hautarzt. 2008 Feb;59(2):151-60 [18214401.001]
  • [Cites] Adv Clin Path. 1999 Jul;3(3):63-8 [10655575.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):28-32 [14631375.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Jan;24(1):30-6 [9020942.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):366-70 [2736482.001]
  • (PMID = 18931983.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


77. Beghin A, Belin S, Hage-Sleiman R, Brunet Manquat S, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon MF, Diaz JJ, Dumontet C: ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. PLoS One; 2009;4(10):e7478
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice.
  • We have previously reported that ADP ribosylation factor like 2 (Arl2), a small GTPase, content influences microtubule dynamics and cell cycle distribution in breast tumor cells, as well as the degree and distribution of phosphorylated P53.
  • Here we show, in two different human breast adenocarcinoma models, that Arl2 content has a major impact on breast tumor cell aggressivity both in vitro and in vivo.
  • A rt-PCR analysis of fresh human tumor breast samples suggested that low Arl2 expression was associated with larger tumor size and greater risk of lymph node involvement at diagnosis.
  • These data underline the role of Arl2, a small GTPase, as an important regulator of breast tumor cell aggressivity, both in vitro and in vivo.
  • [MeSH-major] Breast Neoplasms / metabolism. GTP-Binding Proteins / physiology. Gene Expression Regulation, Neoplastic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2006 Mar;206(3):814-20 [16245300.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):355-68 [16286244.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):241-55 [16598789.001]
  • [Cites] Exp Cell Res. 2007 Feb 1;313(3):473-85 [17188265.001]
  • [Cites] J Biol Chem. 2007 Mar 23;282(12):9117-26 [17255109.001]
  • [Cites] FASEB J. 2008 Jan;22(1):168-82 [17704193.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):3074-82 [18818514.001]
  • [Cites] J Cell Sci. 2006 May 1;119(Pt 9):1801-11 [16608875.001]
  • [Cites] FEBS Lett. 2000 Feb 18;468(1):84-8 [10683446.001]
  • [Cites] Oncogene. 2000 Feb 24;19(9):1191-5 [10713707.001]
  • [Cites] J Cell Biol. 2000 May 29;149(5):1087-96 [10831612.001]
  • [Cites] J Struct Biol. 2001 Aug;135(2):219-29 [11580271.001]
  • [Cites] Dev Cell. 2002 May;2(5):579-91 [12015966.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):94-9 [12524528.001]
  • [Cites] Biochim Biophys Acta. 2003 May 12;1640(2-3):97-104 [12729918.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40829-36 [12912990.001]
  • [Cites] FEBS Lett. 2004 Jan 16;557(1-3):1-8 [14741332.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5614-21 [15328204.001]
  • [Cites] J Biol Chem. 1991 Feb 5;266(4):2606-14 [1899243.001]
  • [Cites] Adv Cancer Res. 1993;61:143-94 [8394044.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):23910-3 [7592580.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1609-20 [8994825.001]
  • [Cites] Genetics. 1997 Jul;146(3):849-57 [9215891.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):821-32 [9265649.001]
  • [Cites] Science. 1998 Oct 9;282(5387):284-7 [9765152.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24054-8 [10446175.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):34-41 [15661531.001]
  • [Cites] Biochem Soc Trans. 2005 Dec;33(Pt 6):1269-72 [16246095.001]
  • [ErratumIn] PLoS One. 2009;4(11):10.1371/annotation/b0d43779-c9aa-44fe-a46d-71d7d2bc4a6a. Hage Sleiman, Rouba [corrected to Hage-Sleiman, Rouba]
  • (PMID = 19829707.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.6.1.- / Arl2 protein, mouse; EC 3.6.1.- / GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2759505
  •  go-up   go-down


78. Wyatt SK, Manning HC, Bai M, Bailey SN, Gallant P, Ma G, McIntosh L, Bornhop DJ: Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol; 2010 Jun;12(3):349-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer.
  • PURPOSE: To quantitatively evaluate the utility of a translocator protein (TSPO)-targeted near-infrared (NIR) probe (NIR-conPK11195) for in vivo molecular imaging of TSPO in breast cancer.
  • PROCEDURES: NIR-conPK11195 uptake and TSPO-specificity were validated in TSPO-expressing human breast adenocarcinoma cells (MDA-MB-231).
  • CONCLUSIONS: NIR-conPK11195 appears to be a promising TSPO-targeted molecular imaging agent for visualization and quantification of breast cancer cells in vivo.
  • This research represents the first study to demonstrate the feasibility of TSPO imaging as an alternative breast cancer imaging approach.
  • [MeSH-major] Breast Neoplasms / diagnosis. Models, Biological. Molecular Imaging / methods. Receptors, GABA / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):785-90 [14550272.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3490-7 [17575211.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Q J Nucl Med. 1998 Mar;42(1):8-17 [9646640.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):488-96 [15189086.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):1-4 [18077528.001]
  • [Cites] J Med Chem. 1997 Aug 1;40(16):2435-9 [9258348.001]
  • [Cites] Prog Neurobiol. 2006 Dec;80(6):308-22 [17156911.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] Acad Radiol. 2008 Apr;15(4):408-16 [18342764.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044005 [16965162.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3205-9 [12374690.001]
  • [Cites] Breast Cancer Res. 2001;3(1):41-6 [11250744.001]
  • [Cites] Eur J Surg Oncol. 2006 Feb;32(1):39-43 [16269226.001]
  • [Cites] Drug Discov Today. 2006 Sep;11(17-18):812-8 [16935749.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23 (8):1664-73 [15755974.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):831-42 [10029072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2767-72 [10706610.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:149S-63S [18523071.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] Mol Imaging Biol. 2006 Jan-Feb;8(1):36-42 [16362149.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2793-9 [16682724.001]
  • [Cites] Trends Pharmacol Sci. 2006 Aug;27(8):402-9 [16822554.001]
  • [Cites] Radiology. 2007 Nov;245(2):333-56 [17940297.001]
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1650-7 [17356607.001]
  • [Cites] JAMA. 2005 Mar 9;293(10):1245-56 [15755947.001]
  • [Cites] J Pharmacol Exp Ther. 1992 Sep;262(3):971-8 [1326631.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2018-23 [17979225.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339-47 [17333178.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):103-21 [18055120.001]
  • [Cites] Phys Med. 2006;21 Suppl 1:12-6 [17645986.001]
  • [Cites] Bioconjug Chem. 2007 Jul-Aug;18(4):1118-22 [17552492.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):322-7 [11745409.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):113-8 [2544689.001]
  • [Cites] Eur J Pharmacol. 1999 Apr 29;371(2-3):197-204 [10357257.001]
  • [Cites] Org Lett. 2002 Apr 4;4(7):1075-8 [11922786.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1144-50 [16000283.001]
  • [Cites] Bioconjug Chem. 2004 Nov-Dec;15(6):1488-95 [15546219.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):168-75 [12558355.001]
  • [Cites] Life Sci. 1999;64(16):1455-64 [10321725.001]
  • [Cites] J Med Chem. 1987 Oct;30(10 ):1901-5 [2821259.001]
  • [Cites] J Recept Signal Transduct Res. 2003;23(2-3):225-38 [14626449.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17 (3):735-40 [16704212.001]
  • [Cites] J Med Chem. 2007 Jan 25;50(2):404-7 [17228885.001]
  • [Cites] J Neurochem. 1983 Dec;41(6):1744-50 [6315880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Feb;84(3):891-5 [3027710.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jun;301(3):1067-78 [12023539.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] Radiology. 1995 Jul;196 (1):123-34 [7784555.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):720-4 [14991243.001]
  • [Cites] Eur Radiol. 2003 Feb;13(2):231-43 [12598985.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):341-9 [17426249.001]
  • (PMID = 19949989.001).
  • [ISSN] 1860-2002
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K25 CA127349
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes; 0 / Receptors, GABA; 0 / TSPO protein, human
  •  go-up   go-down


79. Marioni G, De Filippis C, Ottaviano G, Lorusso M, Staffieri C, Bernini G, Blandamura S: Laryngeal metastasis from sigmoid colon adenocarcinoma followed by peristomal recurrence. Acta Otolaryngol; 2006 Jun;126(6):661-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal metastasis from sigmoid colon adenocarcinoma followed by peristomal recurrence.
  • Cutaneous melanomas are the preponderant primaries metastasizing to the larynx, followed by renal cell carcinomas, breast and lung carcinomas.
  • Colonic adenocarcinoma metastases to the larynx are extremely rare: only 13 cases have been described since 1972.
  • We present the first case of sigmoid colon adenocarcinoma metastasis to the larynx in a patient who developed peristomal malignancy recurrence after total laryngectomy.
  • Patients with metastasis of colonic adenocarcinoma to the larynx usually present with disseminated disease: in view of the poor chances of long-term survival of these patients conservative palliative laryngeal treatments should be carried out to improve the quality of life.
  • [MeSH-major] Adenocarcinoma / secondary. Laryngeal Neoplasms / secondary. Laryngectomy. Neoplasm Recurrence, Local / diagnosis. Sigmoid Neoplasms / diagnosis. Tracheostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720454.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


80. Tisman G: Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report. Tumori; 2009 Nov-Dec;95(6):804-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report.
  • Metastatic breast cancer to the liver is considered incurable.
  • Though many patients with liver metastases may enjoy response to chemo-, immuno- and hormonal therapy, those so inflicted rarely remain disease-free from the time of diagnosis for longer than 6-11 months.
  • A 59-year-old woman with a 4.5-cm invasive ductal, ER-positive/PR-negative, grade III adenocarcinoma of the breast was treated with mastectomy.
  • It is proposed that a possible mechanism for prolonged remission of stage IV breast cancer in this patient may be related to suppression of EGF/HER2 by trastuzumab, thus inhibiting cross-talk-associated tamoxifen/estrogen withdrawal resistance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Receptor Cross-Talk / drug effects. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. EXEMESTANE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210247.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 107868-30-4 / exemestane; 5V9KLZ54CY / Vinblastine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


81. Dasari BV, Lee J, Reid D, Carey D: Ileocecal intussusception due to isolated metastasis from primary esophageal adenocarcinoma. South Med J; 2009 Apr;102(4):419-21
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocecal intussusception due to isolated metastasis from primary esophageal adenocarcinoma.
  • Isolated metastases to the small intestine are rare, but are known to originate from malignant melanoma, or breast or lung cancer.
  • To our knowledge, this is the first reported case of metastases from primary esophageal adenocarcinoma presenting as subacute small bowel obstruction due to ileocecal intussusception.
  • [MeSH-major] Adenocarcinoma / secondary. Cecal Neoplasms / etiology. Esophageal Neoplasms / pathology. Ileal Neoplasms / secondary. Intussusception / etiology
  • [MeSH-minor] Adult. Colonoscopy. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279517.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med; 2007 Oct;131(10):1561-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
  • CONTEXT: Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult.
  • OBJECTIVE: To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin.
  • Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method.
  • Results were validated using 60 cases of metastatic adenocarcinoma with known primaries.
  • RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Neoplasm Proteins / analysis
  • [MeSH-minor] Decision Trees. Female. Humans. Neoplasms, Unknown Primary / chemistry. Neoplasms, Unknown Primary / diagnosis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922593.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


83. Kamer E, Unalp HR, Akguner T, Yigit S, Peskersoy M, Onal MA: [Thick-needle vacuum-assisted biopsy technique for inflammatory breast carcinoma diagnosis]. Acta Cir Bras; 2006 Nov-Dec;21(6):422-4
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thick-needle vacuum-assisted biopsy technique for inflammatory breast carcinoma diagnosis].
  • [Transliterated title] Técnica de biópsia aspirativa por agulha de grosso calibre para o diagnóstico do carcinoma inflamatório da mama.
  • PURPOSE: Inflammatory breast carcinoma (IBC) is a rare clinicopathological cancer type with unique clinical features and a poor prognosis.
  • In this disease, there is generally no palpable mass in the breast.
  • IBC can be mistakenly diagnosed as mastitis and patients may receive a delayed diagnosis and treatment, since these two disorders cause similar pathological appearences on the breast.
  • Clinical suspicion of the disease followed by histopathological observation of occluded dermal lympthatics by tumor emboli leads to definitive diagnosis of IBC.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160256.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] POR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


84. Lau SK, Chu PG, Weiss LM: Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):83-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma.
  • Estrogen receptor (ER) is a useful immunohistochemical marker of breast carcinomas and is commonly used as a means of distinguishing breast carcinomas from adenocarcinomas of other primary sites, including the lung.
  • As such, caution should be exercised in the use of ER immunohistochemistry alone as a means of distinguishing breast carcinomas from lung adenocarcinomas.
  • In the context of an ER-positive lung neoplasm, strong and extensive TTF-1 immunoreactivity can be regarded as strong supportive evidence for a primary bronchogenic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540736.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


85. Wu M, Merajver SD: Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis; 2005-2006;22:25-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy.
  • Inflammatory breast cancer (IBC) presents with unique clinical characteristics (erythema, warming, peau d'orange), rapid progression, and poor survival compared to non-IBC breast cancers.
  • In this review, we discuss the current advances in understanding the genetic determinants of IBC with emphasis on their present and potential applications to diagnosis, prognosis, and treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Breast Neoplasms / genetics. Breast Neoplasms / mortality. Genetic Predisposition to Disease / epidemiology

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735784.001).
  • [ISSN] 0888-6008
  • [Journal-full-title] Breast disease
  • [ISO-abbreviation] Breast Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / R01 CA77612
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 81
  •  go-up   go-down


86. Tanaka H, Umekawa T, Nagao K, Ishihara A, Toyoda N: Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel. Int J Gynecol Cancer; 2005 May-Jun;15(3):568-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel.
  • Histologic examination showed the same morphologic findings as scirrhus type of primary breast carcinoma.
  • This disease was diagnosed as an adenocarcinoma arising in mammary-like glands of the vulva.
  • In our case, the fine-needle aspiration cytology was a rapid and minimally invasive method of diagnosis, and the findings were extremely similar to those of the scirrhus type of primary breast carcinoma.
  • Rapid and accurate diagnosis made with this technique might contribute to a good prognosis in the early-staged cases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882189.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


87. Xavier MH, Vergueiro Tde R, Vilar EG, Pinto JM, Issa MC, Pereira GB, Carocha AP: Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation. Dermatol Online J; 2008;14(11):8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation.
  • The skin is an uncommon site for distant metastasis; when it is present the most common sources are breast, lung, and colon.
  • We report an exuberant and rare case of cutaneous metastasis from gastric adenocarcinoma as the first sign of this serious visceral cancer.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094846.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Pozdnyakova O, Hoang MM, Dresser KA, Mahalingam M: Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma. Arch Pathol Lab Med; 2009 Aug;133(8):1285-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma.
  • CONTEXT: Our recent experience with a patient developing cutaneous metastases within 3 months of diagnosis of esophageal adenocarcinoma suggests that altered expression of the cellular adhesion molecules, E-cadherin and CD44v6, may have had a role to play in the rapid onset of metastases.
  • DESIGN: E-cadherin, beta-catenin, CD44v6, and HER2/neu immunohistochemical stains were performed on archival materials of metastatic adenocarcinoma to the skin from 27 patients and the available corresponding primary tumors in 10 patients.
  • The primary sites included breast (n = 10; 37%), gastrointestinal tract (n = 10; 37%), ovary (n = 1; 4%), thyroid (n = 2; 7%), lung (n = 1; 4%), and unknown primary (n = 3; 11%).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653727.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


89. Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol; 2007 Jun;35(6):370-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
  • The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters.
  • The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions.
  • A positive TTF1 staining supports the diagnosis of metastatic carcinoma originating from lung rather than breast, while a negative TTF1 favors the diagnosis of a breast primary.
  • Immunohistochemical studies with WT1, TTF1, and mCEA antibodies are useful in the differential diagnosis of metastatic adenocarcinomas of lung, breast, and ovary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. CA-125 Antigen / immunology. Carcinoembryonic Antigen / immunology. Nuclear Proteins / immunology. Pleural Effusion, Malignant / diagnosis. Transcription Factors / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497661.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / WT1 Proteins; 0 / thyroid nuclear factor 1
  •  go-up   go-down


90. Serpil O, Meral A, Müzeyyen O, Ozlem T, Umit Y, Mustafa T, Ziya A: Alkaline phosphatase, cytokeratin 7, cytokeratin 8 in the diagnosis of primary lung adenocarcinoma from 148 pleura fluids specimens. Folia Histochem Cytobiol; 2009;47(1):87-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alkaline phosphatase, cytokeratin 7, cytokeratin 8 in the diagnosis of primary lung adenocarcinoma from 148 pleura fluids specimens.
  • Usual primary sites include the lung, breast, gastrointestinal tract, and genitourinary tracts.
  • Predicting the site of origin of an adenocarcinoma can be difficult due to overlapping morphologic characteristics.
  • Thus the AP positive staining largely confirmed the cytologic diagnosis of lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419944.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Keratin-7; 0 / Keratin-8; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


91. Nebesio CL, Goulet RJ Jr, Helft PR, Billings SD: Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma. Int J Dermatol; 2007 Mar;46(3):303-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma.
  • A 50-year-old Caucasian woman with a history of esophageal adenocarcinoma presented with a 3-week history of right breast swelling and progressive erythema.
  • Twenty-two months prior to presentation, she had been diagnosed with adenocarcinoma of the esophagus (T3,N1,M1a) and underwent neoadjuvant chemoradiotherapy followed by surgical resection.
  • On physical examination, the right breast was red, swollen (40% larger than the contralateral breast), tender to palpation, and warm to the touch (Fig. 1).
  • On the basis of the clinical findings, inflammatory breast carcinoma was suspected.
  • A punch biopsy revealed a poorly differentiated adenocarcinoma with extensive involvement of dermal lymphatics (Fig. 2).
  • The clinical and histologic differential diagnosis included inflammatory breast carcinoma vs. metastatic esophageal adenocarcinoma to the skin of the breast.
  • 3), confirming the diagnosis of metastatic esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Breast Neoplasms / secondary. Esophageal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343591.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. El-Ghobashy A, Ohadike C, Wilkinson N, Lane G, Campbell JD: Recurrent urachal mucinous adenocarcinoma presenting as bilateral ovarian tumors on cesarean delivery. Int J Gynecol Cancer; 2009 Dec;19(9):1539-41
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent urachal mucinous adenocarcinoma presenting as bilateral ovarian tumors on cesarean delivery.
  • Secondary ovarian cancers, Krukenberg tumors, are a distinctive subset of metastatic tumors arising from the gastrointestinal tract (stomach, colon, and appendix), the biliary system, the breast, or other genital organs.
  • Primary adenocarcinoma of the bladder accounts for less than 1% of all bladder malignancies; one third of these tumors are urachal in origin.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Cesarean Section. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Urachus
  • [MeSH-minor] Adult. Delivery, Obstetric. Diagnosis, Differential. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955933.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Wood B, Sterrett G, Frost F, Swarbrick N: Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy. Pathology; 2008 Jun;40(4):345-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy.
  • AIMS: To review and illustrate the findings in fine needle biopsy (FNB) of extramammary malignancies presenting with breast metastases (MMB).
  • METHODS: We reviewed 32 cases of MMB diagnosed on breast FNB.
  • The clinical data, with particular attention to the history of a known primary malignancy, previous systemic metastatic disease in other sites and presentation with extramammary disease in addition to a breast mass were examined.
  • There was a history of extramammary malignancy in 26, while in six patients the breast mass was detected at initial presentation with malignant disease.
  • Of the latter six patients, four had evidence of widespread metastases, while one presented with multiple breast masses.
  • Of those patients without known prior malignancy, the majority present with systemic disease or multiple breast lesions.
  • The cytological features allow metastatic disease to be suspected in half of the cases, although in the others, particularly patients with metastatic adenocarcinoma, diagnosis without recourse to immunohistochemistry is difficult or impossible.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Melanoma / secondary. Skin Neoplasms / pathology


94. Angelidou E, Politi E, Sotiropoulou G, Poulianou E, Koutselini H: Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation. Diagn Cytopathol; 2006 Aug;34(8):547-52
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
  • The expression of ER, PR, pS2, and MIB-1 was preoperatively detected by immunocytochemistry in FNAs of 70 patients with breast adenocarcinoma and clinical tumor size up to 2 cm.
  • The findings of the present prospective, multivariate study indicate that NG of the tumor cells, obtained from the preoperative FNAs of breast cancer patients, is a strong predictive marker for the axillary status and in parallel with MIB-1 expression can with sufficient accuracy be of clinical utility.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Nucleus / pathology. Ki-67 Antigen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma / diagnosis. Carcinoma / metabolism. Carcinoma / pathology. Humans. Lymphatic Metastasis / diagnosis. Multivariate Analysis. Neoplasm Staging. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16850494.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / TFF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


95. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
  • Differentiating cells of mesothelial origin from adenocarcinoma (ACA) based on morphology alone can be a diagnostic challenge, especially in cytological specimens.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


96. Luo JD, Liu YY, Zhang XL, Shi LC: [Application of diffusion weighted magnetic resonance imaging to differential diagnosis of breast diseases]. Ai Zheng; 2007 Feb;26(2):168-71
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of diffusion weighted magnetic resonance imaging to differential diagnosis of breast diseases].
  • BACKGROUND & OBJECTIVE: Diffusion weighted imaging (DWI) have been applied to diagnose cerebral diseases, but its application to diagnose breast diseases is in exploring stage.
  • This study was to investigate the value of DWI in differentiating benign and malignant breast lesions.
  • The apparent diffusion coefficients (ADC) of malignant lesions, benign lesions, and normal breast gland were compared.
  • The diagnosis threshold between malignant and benign lesions was decided according to receiver operating characteristic curve (ROC).
  • RESULTS: The ADC values were (1.98+/-0.31) x 10(-3) mm(2)/s for normal breast gland,(1.59+/-0.26) x 10(-3) mm(2)/s for benign lesions, and (0.87+/-0.23) x 10(-3) mm(2)/s for malignant lesions; the 95% reference ranges were (1.38-2.58) x 10(-3) mm(2)/s for normal breast gland, (1.07-2.11) x 10(-3) mm(2)/s for benign lesions, and (0.42-1.32)x10(-3) mm(2)/s for malignant lesions.
  • CONCLUSIONS: ADC value may help to differentiate benign and malignant breast lesions.
  • DWI may be applied to detect breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Fibroadenoma / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Breast / pathology. Breast Cyst / diagnosis. Breast Cyst / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Middle Aged. Papilloma / diagnosis. Papilloma / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298747.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases.
  • Breast metastases from extra-mammary malignancies, especially those mimicking primary inflammatory breast carcinoma, are extremely rare.
  • We report here two cases of inflammatory breast metastases from gastric or ovarian cancer.
  • Both patients, who had prior advanced malignant disease, presented with unilateral breast redness and swelling with peau d'orange sign, resembling primary inflammatory breast cancer or acute mastitis.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • Since breast metastasis is a sign of poor prognosis of the primary malignant disease, the possibility of breast metastasis should be considered in appropriate patients to preclude unnecessary major surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


98. Ong CA, Lao-Sirieix P, Fitzgerald RC: Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol; 2010 Dec 07;16(45):5669-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.
  • It is clinically important due to the increased risk (0.5% per annum) of progression to esophageal adenocarcinoma (EA), which has a poor outcome unless diagnosed early.
  • This is in contrast to other cancers like breast and prostate for which biomarkers are utilized routinely to inform clinical decisions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers, Tumor / analysis. Esophageal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Clin Pathol. 2005 Aug 12;5:7 [16095543.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] BMJ. 2009;338:b604 [19336487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Methods Inf Med. 2001 Mar;40(1):1-5 [11310153.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Dis Esophagus. 2004;17(2):136-40 [15230726.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1030-4 [9067264.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):58-65 [18820669.001]
  • [Cites] Lancet. 2003 Nov 1;362(9394):1439-44 [14602436.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2738-41 [15102678.001]
  • [Cites] BMJ. 2009;338:b375 [19237405.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):387-91 [16106245.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Genome Res. 1999 May;9(5):482-91 [10330128.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 1;30(7):e28 [11917034.001]
  • [Cites] Surg Endosc. 2010 May;24(5):1144-50 [19997751.001]
  • [Cites] BMC Cancer. 2008;8:254 [18778486.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3789-98 [16785472.001]
  • [Cites] Nat Rev Genet. 2010 Mar;11(3):191-203 [20125086.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3459-70 [18825457.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] BMJ. 2009;338:b606 [19502216.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):748-54 [16401681.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):351-8 [15688381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9523-7 [1946366.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1523-30 [20461069.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Dis Esophagus. 2008;21(2):97-102 [18269642.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gastroenterology. 2010 Dec;139(6):1995-2004.e15 [20621683.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2153-60 [19584833.001]
  • [Cites] BMC Cancer. 2006;6:134 [16712734.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 1;23(5):587-93 [16480397.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):264-8 [16477636.001]
  • [Cites] Mol Pathol. 2003 Dec;56(6):313-7 [14645692.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Scand J Gastroenterol. 2007 Nov;42(11):1271-4 [17852872.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Dis Esophagus. 2003;16(1):17-23 [12581249.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1755-63 [9676852.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3602-9 [17896157.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4112-5 [19435894.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2284-9 [9122186.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):865-70 [10732760.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):786-94 [16921482.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Scand J Gastroenterol. 2007 Jun;42(6):682-8 [17505989.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):330-7 [20028767.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):1933-7 [10928129.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Med. 2010 May;123(5):462-7 [20399324.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8279-87 [19088045.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6192-200 [19789312.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]
  • [Cites] Cancer. 2008 May 15;112(10):2173-80 [18348304.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1800-7 [12055587.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1093-6 [19417749.001]
  • [Cites] Drug Discov Today. 2005 Jul 15;10(14):965-76 [16023055.001]
  • [Cites] Ann Thorac Surg. 2001 Sep;72(3):859-66 [11565671.001]
  • [Cites] Am J Gastroenterol. 2009 Oct;104(10):2588-94 [19623166.001]
  • [Cites] N Engl J Med. 1976 Aug 26;295(9):476-80 [940579.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Cancer Metastasis Rev. 2009 Dec;28(3-4):317-26 [19997771.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):955-61 [16153457.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • (PMID = 21128316.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2997982
  •  go-up   go-down


99. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Chromosomes, Human, Pair 17 / genetics. Diagnosis, Differential. Female. Gene Amplification. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


100. Lee HG, Lee B, Kim SM, Suh BJ, Yu HJ: A case of gastric adenocarcinoma presenting as meningeal carcinomatosis. Korean J Intern Med; 2007 Dec;22(4):304-7
Hazardous Substances Data Bank. D-MANNITOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of gastric adenocarcinoma presenting as meningeal carcinomatosis.
  • The most common cancers involving the leptomeninges are breast, lung cancer and melanoma.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis.
  • The endoscopy showed a thickening of the folds of the stomach compatible with the diagnosis of a Borrman type IV gastric cancer.
  • The cytology examination of the cerebrospinal fluid supported the diagnosis of metastatic signet ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Meningeal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):165-70 [12714889.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):255-60 [16344918.001]
  • [Cites] Neurology. 1999 Jul 22;53(2):382-5 [10430430.001]
  • [Cites] J Neurooncol. 1999 May;43(1):59-62 [10448872.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):577-9 [15827450.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):315-8 [15851093.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv285-91 [15477323.001]
  • (PMID = 18309694.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ PMC2687665
  •  go-up   go-down






Advertisement